Journal Article
. 2020 May; 382(20):1894-1905.
doi: 10.1056/NEJMoa1915745.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S Finn 1 Shukui Qin 1 Masafumi Ikeda 1 Peter R Galle 1 Michel Ducreux 1 Tae-You Kim 1 Masatoshi Kudo 1 Valeriy Breder 1 Philippe Merle 1 Ahmed O Kaseb 1 Daneng Li 1 Wendy Verret 1 Derek-Zhen Xu 1 Sairy Hernandez 1 Juan Liu 1 Chen Huang 1 Sohail Mulla 1 Yulei Wang 1 Ho Yeong Lim 1 Andrew X Zhu 1 Ann-Lii Cheng 1 IMbrave150 Investigators  
Affiliations
  • PMID: 32402160
  •     929 citations

Abstract

Background: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.

Methods: In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

Results: The intention-to-treat population included 336 patients in the atezolizumab-bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab-bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab-bevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumab-bevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab-bevacizumab group; however, other high-grade toxic effects were infrequent.

Conclusions: In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.).

Does this patient have COVID-19? A practical guide for the internist.
Lorenzo Bertolino, Martina Vitrone, Emanuele Durante-Mangoni.
Intern Emerg Med, 2020 May 24; 15(5). PMID: 32445165    Free PMC article.
Review.
Learning from the past: did experience with previous epidemics help mitigate the impact of COVID-19 among spine surgeons worldwide?
Joseph A Weiner, Peter R Swiatek, +12 authors, Dino Samartzis.
Eur Spine J, 2020 Jun 06; 29(8). PMID: 32500177    Free PMC article.
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective.
Aisling Barry, Smith Apisarnthanarax, +16 authors, Maria A Hawkins.
Lancet Gastroenterol Hepatol, 2020 Jun 09; 5(8). PMID: 32511951    Free PMC article.
Review.
Chest X-ray in new Coronavirus Disease 2019 (COVID-19) infection: findings and correlation with clinical outcome.
Diletta Cozzi, Marco Albanesi, +7 authors, Vittorio Miele.
Radiol Med, 2020 Jun 11; 125(8). PMID: 32519256    Free PMC article.
Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Hua Qin, Andong Zhao.
Protein Cell, 2020 Jun 11; 11(10). PMID: 32519302    Free PMC article.
Review.
Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma.
Angélique Saint, Maxime Benchetrit, +4 authors, Jérome Barriere.
Therap Adv Gastroenterol, 2020 Jul 03; 13. PMID: 32612680    Free PMC article.
Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.
Jiao Feng, Jingjing Li, +5 authors, Chuanyong Guo.
J Exp Clin Cancer Res, 2020 Jul 08; 39(1). PMID: 32631382    Free PMC article.
Review.
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment.
Federico Piñero, Melisa Dirchwolf, Mário G Pessôa.
Cells, 2020 Jun 05; 9(6). PMID: 32492896    Free PMC article.
Review.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Gaia Giannone, Eleonora Ghisoni, +4 authors, Giorgio Valabrega.
Int J Mol Sci, 2020 Jun 25; 21(12). PMID: 32575899    Free PMC article.
Review.
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.
Monica Mossenta, Davide Busato, Michele Dal Bo, Giuseppe Toffoli.
Cancers (Basel), 2020 Jun 27; 12(6). PMID: 32585931    Free PMC article.
Review.
Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma.
Lucile Dumolard, Julien Ghelfi, +2 authors, Zuzana Macek Jilkova.
Int J Mol Sci, 2020 Jun 25; 21(12). PMID: 32575734    Free PMC article.
Review.
Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.
Neil Mehta, Neehar D Parikh, +2 authors, Amit G Singal.
Clin Gastroenterol Hepatol, 2020 Jul 12; 19(8). PMID: 32652308    Free PMC article.
Review.
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.
Jörg Trojan.
Drugs, 2020 Jul 17; 80(12). PMID: 32671719    Free PMC article.
Review.
Targeted therapy for hepatocellular carcinoma.
Ao Huang, Xin-Rong Yang, +2 authors, Jian Zhou.
Signal Transduct Target Ther, 2020 Aug 13; 5(1). PMID: 32782275    Free PMC article.
Review.
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.
Di-Yang Xie, Zheng-Gang Ren, +2 authors, Qiang Gao.
Hepatobiliary Surg Nutr, 2020 Aug 25; 9(4). PMID: 32832496    Free PMC article.
Review.
A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma.
Masatoshi Kudo.
Hepatobiliary Surg Nutr, 2020 Aug 25; 9(4). PMID: 32832511    Free PMC article.
Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study.
Won-Mook Choi, Danbi Lee, +8 authors, Jonggi Choi.
Cancers (Basel), 2020 Jul 24; 12(7). PMID: 32698355    Free PMC article.
Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma.
Jun Gong, Jeremy Chuang, +3 authors, Daneng Li.
Int J Mol Sci, 2020 Jul 29; 21(15). PMID: 32718047    Free PMC article.
Review.
An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma.
Ying Hu, Huaibo Sun, Henghui Zhang, Xianbo Wang.
Front Oncol, 2020 Aug 28; 10. PMID: 32850343    Free PMC article.
Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
Anita Mazloom, Nima Ghalehsari, +5 authors, Uqba Khan.
J Clin Med, 2020 Aug 13; 9(8). PMID: 32781500    Free PMC article.
Review.
Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization.
Naoshi Odagiri, Hoang Hai, +8 authors, Norifumi Kawada.
Cancers (Basel), 2020 Jul 30; 12(8). PMID: 32722224    Free PMC article.
Telomeres and Telomerase in the Development of Liver Cancer.
Lena In der Stroth, Umesh Tharehalli, Cagatay Günes, André Lechel.
Cancers (Basel), 2020 Jul 30; 12(8). PMID: 32722302    Free PMC article.
Review.
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis.
Giuseppe Cabibbo, Ciro Celsa, +8 authors, Calogero Cammà.
Cancers (Basel), 2020 Aug 06; 12(8). PMID: 32752060    Free PMC article.
HSP70-eIF4G Interaction Promotes Protein Synthesis and Cell Proliferation in Hepatocellular Carcinoma.
Meng Wang, Kai Wei, +4 authors, Katrin Hoffmann.
Cancers (Basel), 2020 Aug 23; 12(8). PMID: 32823513    Free PMC article.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, +17 authors, Josep M Llovet.
J Clin Oncol, 2020 Jul 28; 38(26). PMID: 32716739    Free PMC article.
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
Petros Fessas, Ahmed Kaseb, +24 authors, David J Pinato.
J Immunother Cancer, 2020 Sep 02; 8(2). PMID: 32868393    Free PMC article.
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
Yuji Eso, Hiroshi Seno.
Therap Adv Gastroenterol, 2020 Sep 12; 13. PMID: 32913444    Free PMC article.
Review.
Therapy of Primary Liver Cancer.
Mei Feng, Yisheng Pan, Ruirui Kong, Shaokun Shu.
Innovation (N Y), 2020 Sep 12; 1(2). PMID: 32914142    Free PMC article.
Review.
Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer.
Yoshiro Itatani, Takamasa Yamamoto, +5 authors, Napoleone Ferrara.
Proc Natl Acad Sci U S A, 2020 Aug 21; 117(35). PMID: 32817421    Free PMC article.
Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
Michela Guardascione, Giuseppe Toffoli.
Int J Mol Sci, 2020 Sep 04; 21(17). PMID: 32878115    Free PMC article.
Review.
Targeting STAT3 in Cancer Immunotherapy.
Sailan Zou, Qiyu Tong, +3 authors, Xianghui Fu.
Mol Cancer, 2020 Sep 26; 19(1). PMID: 32972405    Free PMC article.
Review.
Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients.
Ajalaya Teyateeti, Armeen Mahvash, +10 authors, S Cheenu Kappadath.
J Hepatocell Carcinoma, 2020 Sep 29; 7. PMID: 32984089    Free PMC article.
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date.
Alison L Raybould, Hanna Sanoff.
J Hepatocell Carcinoma, 2020 Sep 29; 7. PMID: 32984090    Free PMC article.
Review.
Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
Di Ma, Juan Wang, +2 authors, Zhiyong Wang.
BMC Cancer, 2020 Oct 01; 20(1). PMID: 32993568    Free PMC article.
A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2020 Oct 02; 9(4). PMID: 32999864    Free PMC article.
Hypoxia-inducible factors and innate immunity in liver cancer.
Vincent Wai-Hin Yuen, Carmen Chak-Lui Wong.
J Clin Invest, 2020 Aug 05; 130(10). PMID: 32750043    Free PMC article.
Review.
Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.
Leon Schönfeld, Jan B Hinrichs, +7 authors, Martha M Kirstein.
J Cancer Res Clin Oncol, 2020 Jun 22; 146(11). PMID: 32564137    Free PMC article.
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
Graziana Digiacomo, Claudia Fumarola, +8 authors, Pier Giorgio Petronini.
Front Oncol, 2020 Oct 20; 10. PMID: 33072590    Free PMC article.
Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2020 Oct 22; 9(5). PMID: 33083276    Free PMC article.
Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.
Robin Park, Fariha Eshrat, +2 authors, Anwaar Saeed.
Vaccines (Basel), 2020 Aug 14; 8(3). PMID: 32784389    Free PMC article.
Review.
Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study.
Anwaar Saeed, Hannah Hildebrand, +9 authors, Weijing Sun.
J Clin Med, 2020 Aug 23; 9(9). PMID: 32824968    Free PMC article.
Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers.
Leonard Kaps, Detlef Schuppan.
Cells, 2020 Sep 10; 9(9). PMID: 32899119    Free PMC article.
Review.
Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma.
Sophia Heinrich, Darko Castven, Peter R Galle, Jens U Marquardt.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899197    Free PMC article.
Review.
Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients.
Suresh Gopi Kalathil, Katy Wang, +2 authors, Yasmin Thanavala.
Oncoimmunology, 2020 Oct 27; 9(1). PMID: 33101775    Free PMC article.
Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma.
Alexander A Azizi, Andreas V Hadjinicolaou, +2 authors, Bristi Basu.
Front Oncol, 2020 Oct 27; 10. PMID: 33102226    Free PMC article.
Review.
Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer.
Isabella Lurje, Linda Hammerich, Frank Tacke.
Int J Mol Sci, 2020 Oct 11; 21(19). PMID: 33036244    Free PMC article.
Review.
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.
Tomoko Aoki, Masatoshi Kudo, +8 authors, Naoshi Nishida.
Cancers (Basel), 2020 Oct 24; 12(10). PMID: 33092011    Free PMC article.
Novel Therapies for Hepatocellular Carcinoma.
Lorenza Rimassa.
Cancers (Basel), 2020 Oct 24; 12(10). PMID: 33092015    Free PMC article.
Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor.
Florian Bösch, Annelore Altendorf-Hofmann, +8 authors, Thomas Knösel.
J Clin Med, 2020 Oct 25; 9(10). PMID: 33096620    Free PMC article.
Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment.
Maria L Martínez-Chantar, Matias A Avila, Shelly C Lu.
Cancers (Basel), 2020 Sep 27; 12(10). PMID: 32977536    Free PMC article.
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update.
Christo Kole, Nikolaos Charalampakis, +6 authors, Dimitrios Schizas.
Cancers (Basel), 2020 Oct 07; 12(10). PMID: 33020428    Free PMC article.
Review.
Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy.
Marina Ohkoshi-Yamada, Kenya Kamimura, +23 authors, Shuji Terai.
Cancers (Basel), 2020 Oct 18; 12(10). PMID: 33066141    Free PMC article.
Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib.
Katharina Pomej, Bernhard Scheiner, +8 authors, Matthias Pinter.
Cancers (Basel), 2020 Oct 18; 12(10). PMID: 33066190    Free PMC article.
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
Ian Chau, Nicolas Penel, +14 authors, Charles S Fuchs.
Cancers (Basel), 2020 Oct 21; 12(10). PMID: 33076423    Free PMC article.
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
Piera Federico, Angelica Petrillo, +8 authors, Bruno Daniele.
Cancers (Basel), 2020 Oct 22; 12(10). PMID: 33080958    Free PMC article.
Review.
Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus.
Cecilia Monge Bonilla, Nicole A McGrath, Jianyang Fu, Changqing Xie.
Hepatoma Res, 2020 Nov 03; 6. PMID: 33134550    Free PMC article.
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.
Maite G Fernández-Barrena, María Arechederra, +2 authors, Matias A Avila.
JHEP Rep, 2020 Nov 03; 2(6). PMID: 33134907    Free PMC article.
Review.
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Mohamad Bassam Sonbol, Irbaz Bin Riaz, +15 authors, Tanios Bekaii-Saab.
JAMA Oncol, 2020 Oct 23; 6(12). PMID: 33090186    Free PMC article.
Systematic Review.
Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection.
Fuchen Liu, Xinggang Guo, +7 authors, Hui Liu.
Int J Biol Sci, 2020 Nov 10; 16(16). PMID: 33162826    Free PMC article.
Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study.
Ning Lyu, Yanan Kong, +9 authors, Ming Zhao.
Front Oncol, 2020 Nov 10; 10. PMID: 33163408    Free PMC article.
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
Shixue Chen, Ziwei Huang, +12 authors, Yi Hu.
J Hepatocell Carcinoma, 2020 Nov 12; 7. PMID: 33173757    Free PMC article.
Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations.
Qi Zhang, Yiwen Chen, Xueli Bai, Tingbo Liang.
Front Oncol, 2020 Nov 13; 10. PMID: 33178615    Free PMC article.
Review.
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
Yuchen Liu, Xiaohui Wang, Yingzi Yang.
Clin Mol Hepatol, 2020 Sep 29; 26(4). PMID: 32981290    Free PMC article.
Review.
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma.
Young Chang, Soung Won Jeong, Jae Young Jang, Yong Jae Kim.
Int J Mol Sci, 2020 Nov 05; 21(21). PMID: 33142892    Free PMC article.
Review.
PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
Tian-En Li, Shun Wang, +10 authors, Lun-Xiu Qin.
Front Immunol, 2020 Nov 17; 11. PMID: 33193421    Free PMC article.
TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma.
Jiawei Rao, Xukun Wu, +2 authors, Yi Ma.
Front Genet, 2020 Nov 17; 11. PMID: 33193690    Free PMC article.
In situ tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor.
Chen Chen, Shengchang Zhang, +11 authors, Xinyi Jiang.
Theranostics, 2020 Nov 19; 10(26). PMID: 33204325    Free PMC article.
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
Eleonora De Martin, Jean-Marie Michot, +2 authors, Didier Samuel.
JHEP Rep, 2020 Nov 19; 2(6). PMID: 33205034    Free PMC article.
Review.
Management of patients with intermediate stage hepatocellular carcinoma.
David Prince, Ken Liu, +4 authors, Jiansong Ji.
Ther Adv Med Oncol, 2020 Nov 24; 12. PMID: 33224278    Free PMC article.
Review.
Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy.
Won Jin Ho, Gaurav Sharma, +10 authors, Mark Yarchoan.
J Immunother Cancer, 2020 Nov 22; 8(2). PMID: 33219090    Free PMC article.
Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma.
Tian-Ming Cui, Yao Liu, Jia-Bei Wang, Lian-Xin Liu.
Onco Targets Ther, 2020 Nov 26; 13. PMID: 33235462    Free PMC article.
Review.
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer.
Panagiotis Ntellas, Leonidas Mavroeidis, +9 authors, George Pentheroudakis.
Cancers (Basel), 2020 Oct 31; 12(11). PMID: 33121034    Free PMC article.
Review.
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.
Sridhar Nimmagadda.
Cancers (Basel), 2020 Nov 04; 12(11). PMID: 33137949    Free PMC article.
Review.
The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma.
Bart Vanderborght, Sander Lefere, Hans Van Vlierberghe, Lindsey Devisscher.
Cells, 2020 Nov 05; 9(11). PMID: 33143149    Free PMC article.
Review.
The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions.
Karam Khaddour, Tanner M Johanns, George Ansstas.
Pharmaceuticals (Basel), 2020 Nov 19; 13(11). PMID: 33202642    Free PMC article.
Review.
Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses Against Hepatocellular Carcinoma.
Leyre Silva, Josune Egea, +10 authors, Pablo Sarobe.
Cancers (Basel), 2020 Nov 20; 12(11). PMID: 33207844    Free PMC article.
Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry.
Thierry de Baere, Boris Guiu, +8 authors, Gontran Verset.
Cancers (Basel), 2020 Nov 21; 12(11). PMID: 33212917    Free PMC article.
The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
Alessandra Leong, Minah Kim.
Int J Mol Sci, 2020 Nov 22; 21(22). PMID: 33217955    Free PMC article.
Review.
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Stephen P Hack, Andrew X Zhu, Yulei Wang.
Front Immunol, 2020 Dec 01; 11. PMID: 33250900    Free PMC article.
Review.
Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability.
Joseph L Jilek, Mei-Juan Tu, Chao Zhang, Ai-Ming Yu.
Drug Metab Dispos, 2020 Oct 15; 48(12). PMID: 33051247    Free PMC article.
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Francesco Tovoli, Stefania De Lorenzo, Franco Trevisani.
Vaccines (Basel), 2020 Oct 08; 8(4). PMID: 33023131    Free PMC article.
Review.
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.
Giulia Orsi, Francesco Tovoli, +23 authors, Andrea Casadei-Gardini.
Target Oncol, 2020 Oct 13; 15(6). PMID: 33044683
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
Mohamed A Abd El Aziz, Antonio Facciorusso, +4 authors, Rodolfo Sacco.
Vaccines (Basel), 2020 Oct 23; 8(4). PMID: 33086471    Free PMC article.
Review.
Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.
Mark Farha, Neil K Jairath, Theodore S Lawrence, Issam El Naqa.
JCO Clin Cancer Inform, 2020 Nov 03; 4. PMID: 33136432    Free PMC article.
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Kohei Shigeta, Aya Matsui, +23 authors, Dan G Duda.
J Immunother Cancer, 2020 Nov 26; 8(2). PMID: 33234602    Free PMC article.
Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries.
Khaled Abouelezz, Dipen Khanapara, +2 authors, Helal F Hetta.
Cancer Manag Res, 2020 Dec 05; 12. PMID: 33273860    Free PMC article.
Review.
The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
Jisheng Li, Lei Cong, +7 authors, Xiangling Wang.
Front Oncol, 2020 Dec 08; 10. PMID: 33282742    Free PMC article.
Recent updates on Sintilimab in solid tumor immunotherapy.
Xuhong Liu, Yong Yi.
Biomark Res, 2020 Dec 10; 8(1). PMID: 33292551    Free PMC article.
Review.
Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review.
Kaili Yang, Jiarui Li, +2 authors, Chunmei Bai.
Ther Adv Med Oncol, 2020 Dec 10; 12. PMID: 33294036    Free PMC article.
Review.
Conversion surgery for hepatocellular carcinoma in the new era of targeted and immune checkpoint inhibitor therapies.
Lei Zhao, Haitao Zhao.
Hepatobiliary Surg Nutr, 2020 Dec 11; 9(6). PMID: 33299842    Free PMC article.
Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient.
Er-Lei Zhang, Zun-Yi Zhang, Jian Li, Zhi-Yong Huang.
Onco Targets Ther, 2020 Dec 15; 13. PMID: 33311988    Free PMC article.
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy.
Lydia S Lamb, Hao-Wen Sim, Ann I McCormack.
Front Endocrinol (Lausanne), 2020 Dec 15; 11. PMID: 33312158    Free PMC article.
Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva.
World J Transplant, 2020 Dec 15; 10(11). PMID: 33312891    Free PMC article.
Review.
Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma.
Zachary T Berman, Isabel Newton.
Semin Intervent Radiol, 2020 Dec 18; 37(5). PMID: 33328699    Free PMC article.
Review.
Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Guosheng Yuan, Xiao Cheng, +11 authors, Jinzhang Chen.
Onco Targets Ther, 2020 Dec 18; 13. PMID: 33328740    Free PMC article.
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy.
Pil Soo Sung, Moon Hyung Choi, +8 authors, Si Hyun Bae.
Front Oncol, 2020 Dec 18; 10. PMID: 33330098    Free PMC article.
Clinical implications of WNT/β-catenin signaling for hepatocellular carcinoma.
Yoshinari Asaoka, Atsushi Tanaka.
Glob Health Med, 2020 Dec 18; 2(5). PMID: 33330820    Free PMC article.
Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics.
Taiji Yamazoe, Taizo Mori, Sachiyo Yoshio, Tatsuya Kanto.
Glob Health Med, 2020 Dec 18; 2(5). PMID: 33330821    Free PMC article.
Review.
Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines.
Kyoji Ito, Nobuyuki Takemura, +2 authors, Norihiro Kokudo.
Glob Health Med, 2020 Dec 18; 2(5). PMID: 33330822    Free PMC article.
Review.
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Yanli Hou, Bin Wu.
Cancer Commun (Lond), 2020 Nov 08; 40(12). PMID: 33159490    Free PMC article.
The evolving treatment landscape of hepatocellular carcinoma: more choices, more responsibility.
S Gill.
Curr Oncol, 2020 Dec 22; 27(Suppl 3). PMID: 33343206    Free PMC article.
Current locoregional therapies and treatment strategies in hepatocellular carcinoma.
L Cardarelli-Leite, A Hadjivassiliou, +6 authors, D M Liu.
Curr Oncol, 2020 Dec 22; 27(Suppl 3). PMID: 33343208    Free PMC article.
Review.
Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
A Weinmann, P R Galle.
Curr Oncol, 2020 Dec 22; 27(Suppl 3). PMID: 33343209    Free PMC article.
Review.
Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
S Perera, D Kelly, G M O'Kane.
Curr Oncol, 2020 Dec 22; 27(Suppl 3). PMID: 33343210    Free PMC article.
Review.
Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
C P Amaro, V C Tam.
Curr Oncol, 2020 Dec 22; 27(Suppl 3). PMID: 33343211    Free PMC article.
Review.
Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis.
Sumera Bukhari, Kristine Ward, Michael Styler.
Case Rep Oncol Med, 2020 Dec 22; 2020. PMID: 33343953    Free PMC article.
Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.
Farzam Vaziri, Steven Colquhoun, Yu-Jui Yvonne Wan.
Liver Res, 2020 Dec 22; 4(4). PMID: 33343967    Free PMC article.
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.
Karan Mediratta, Sara El-Sahli, Vanessa D'Costa, Lisheng Wang.
Cancers (Basel), 2020 Dec 02; 12(12). PMID: 33256070    Free PMC article.
Review.
Human Hepatocellular Carcinoma (HCC).
Luigi Buonaguro.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322652    Free PMC article.
Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.
Saleh A Alqahtani, Faisal M Sanai, +9 authors, Waleed K Al-Hamoudi.
Saudi J Gastroenterol, 2020 Oct 21; 26(Suppl 1). PMID: 33078723    Free PMC article.
Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection.
Hannah Miller, Zoltan Czigany, +10 authors, Georg Lurje.
Cancers (Basel), 2020 Dec 24; 12(12). PMID: 33352897    Free PMC article.
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma.
Stephan Spahn, Daniel Roessler, +13 authors, Michael Bitzer.
Cancers (Basel), 2020 Dec 24; 12(12). PMID: 33353145    Free PMC article.
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion.
Sojung Han, Hye Won Lee, +8 authors, Beom Kyung Kim.
J Hepatocell Carcinoma, 2020 Dec 29; 7. PMID: 33365287    Free PMC article.
Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion.
Laura Kulik, Leonardo G da Fonseca, +4 authors, Peter R Galle.
J Hepatocell Carcinoma, 2020 Dec 31; 7. PMID: 33376711    Free PMC article.
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
Jaejun Lee, Pil Soo Sung, +13 authors, Seung Kew Yoon.
J Clin Med, 2020 Dec 30; 9(12). PMID: 33371271    Free PMC article.
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
Benjamin Ruf, Bernd Heinrich, Tim F Greten.
Cell Mol Immunol, 2020 Nov 26; 18(1). PMID: 33235387    Free PMC article.
Review.
Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.
Matthew R Woeste, Anne E Geller, Robert C G Martin, Hiram C Polk.
Ann Surg Oncol, 2021 Jan 05; 28(3). PMID: 33393028
Review.
Hepatocellular carcinoma: old friends and new tricks.
Eunsun Kim, Patrick Viatour.
Exp Mol Med, 2020 Dec 04; 52(12). PMID: 33268834    Free PMC article.
Review.
A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
Zaoqu Liu, Yuyuan Zhang, +5 authors, Xinwei Han.
J Transl Med, 2021 Jan 08; 19(1). PMID: 33407585    Free PMC article.
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
Johann von Felden, Amanda J Craig, +13 authors, Augusto Villanueva.
Oncogene, 2020 Oct 25; 40(1). PMID: 33097857
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Meghan M Bell, Nicholas T Gutsche, +4 authors, Freddy E Escorcia.
Molecules, 2020 Dec 31; 26(1). PMID: 33374953    Free PMC article.
Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma.
Ji Won Han, Seung Kew Yoon.
Int J Mol Sci, 2021 Jan 01; 22(1). PMID: 33379384    Free PMC article.
Review.
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
Dong-Hoon Yeom, Yo-Seob Lee, +9 authors, Weon-Kyoo You.
Int J Mol Sci, 2021 Jan 02; 22(1). PMID: 33383646    Free PMC article.
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
Giuseppe Cabibbo, Ciro Celsa, +8 authors, Calogero Cammà.
Cancers (Basel), 2021 Jan 06; 13(1). PMID: 33396833    Free PMC article.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
Paolo A Ascierto, Lisa H Butterfield, +17 authors, Igor Puzanov.
J Transl Med, 2021 Jan 08; 19(1). PMID: 33407605    Free PMC article.
Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience.
Wei-Fan Hsu, Po-Heng Chuang, +10 authors, Cheng-Yuan Peng.
Am J Cancer Res, 2021 Jan 09; 10(12). PMID: 33415018    Free PMC article.
T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.
Jin Bian, Jianzhen Lin, +5 authors, Haitao Zhao.
Am J Cancer Res, 2021 Jan 09; 10(12). PMID: 33415021    Free PMC article.
Review.
A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.
Olga Raevskaya, Henry Appelman, Nataliya Razumilava.
Curr Hepatol Rep, 2021 Jan 09; 19(4). PMID: 33415066    Free PMC article.
Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies.
Danielle L Stolley, Anna Colleen Crouch, +4 authors, Erik N K Cressman.
Pharmaceutics, 2021 Jan 10; 12(12). PMID: 33419304    Free PMC article.
Review.
Extracellular vesicle-associated organotropic metastasis.
Zhenzhen Mo, Jia Yang Alex Cheong, +3 authors, Daniel Xin Zhang.
Cell Prolif, 2020 Nov 05; 54(1). PMID: 33145869    Free PMC article.
Review.
Development and Validation of a Combined Ferroptosis and Immune Prognostic Classifier for Hepatocellular Carcinoma.
Yang Liu, Xi Zhang, +3 authors, Zewen Song.
Front Cell Dev Biol, 2021 Jan 12; 8. PMID: 33425905    Free PMC article.
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma.
Phuong H D Nguyen, Siming Ma, +27 authors, Valerie Chew.
Nat Commun, 2021 Jan 13; 12(1). PMID: 33431814    Free PMC article.
Current perspectives on the tumor microenvironment in hepatocellular carcinoma.
Cositha Santhakumar, Edward J Gane, Ken Liu, Geoffrey W McCaughan.
Hepatol Int, 2020 Nov 15; 14(6). PMID: 33188512
Review.
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Anwaar Saeed, Robin Park, Weijing Sun.
J Hematol Oncol, 2021 Jan 14; 14(1). PMID: 33436042    Free PMC article.
Systematic Review.
Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres.
Xi Li, S Ali Montazeri, +7 authors, Beau Toskich.
Eur J Nucl Med Mol Imaging, 2021 Jan 14; 48(8). PMID: 33438101
Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma: Acknowledgments.
Diamantis I Tsilimigras, Timothy M Pawlik.
Ann Transl Med, 2021 Jan 14; 8(23). PMID: 33437756    Free PMC article.
Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma.
Yannick Sebastiaan Rakké, Dave Sprengers, Jaap Kwekkeboom, Jan Nicolaas Maria IJzermans.
Ann Transl Med, 2021 Jan 14; 8(23). PMID: 33437813    Free PMC article.
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
Matthias Pinter, Bernhard Scheiner, Markus Peck-Radosavljevic.
Gut, 2020 Aug 05; 70(1). PMID: 32747413    Free PMC article.
Review.
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2021 Jan 15; 9(6). PMID: 33442537    Free PMC article.
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.
Masatoshi Kudo.
Liver Cancer, 2021 Jan 15; 9(6). PMID: 33442538    Free PMC article.
Review.
Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study.
Shou-Sheng Chu, Yu-Hsuan Kuo, +5 authors, Hung-Chang Wu.
Sci Rep, 2021 Jan 17; 11(1). PMID: 33452421    Free PMC article.
Hepatocellular carcinoma.
Josep M Llovet, Robin Kate Kelley, +7 authors, Richard S Finn.
Nat Rev Dis Primers, 2021 Jan 23; 7(1). PMID: 33479224
Review.
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview.
Diederick J van Doorn, Robert Bart Takkenberg, Heinz-Josef Klümpen.
Pharmaceuticals (Basel), 2020 Dec 31; 14(1). PMID: 33374927    Free PMC article.
Review.
Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma.
M Nakano, R Kuromatsu, +9 authors, Kurume Liver Cancer Study Group of Japan.
ESMO Open, 2021 Jan 06; 6(1). PMID: 33399083    Free PMC article.
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.
Shigeo Shimose, Hideki Iwamoto, +13 authors, Takuji Torimura.
Cancers (Basel), 2021 Jan 21; 13(1). PMID: 33466496    Free PMC article.
Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives.
Daniel M Girardi, Jana Priscila M Pacífico, +3 authors, Allan A L Pereira.
Pharmaceuticals (Basel), 2021 Jan 06; 14(1). PMID: 33396181    Free PMC article.
Review.
Lenvatinib for Hepatocellular Carcinoma: A Literature Review.
Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki.
Pharmaceuticals (Basel), 2021 Jan 10; 14(1). PMID: 33418941    Free PMC article.
Review.
Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial.
Salomon M Stemmer, Nebojsa S Manojlovic, +18 authors, Pnina Fishman.
Cancers (Basel), 2021 Jan 13; 13(2). PMID: 33430312    Free PMC article.
Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis.
Ilario Giovanni Rapposelli, Serena De Matteis, +9 authors, Andrea Casadei-Gardini.
Cancers (Basel), 2021 Jan 13; 13(2). PMID: 33430142    Free PMC article.
The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma.
Philippe Merle.
Cancers (Basel), 2021 Jan 15; 13(2). PMID: 33440630    Free PMC article.
Review.
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials.
Philippe Rochigneux, Brice Chanez, +3 authors, Marine Gilabert.
Cancers (Basel), 2021 Jan 17; 13(2). PMID: 33450845    Free PMC article.
Review.
Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.
Guosheng Yuan, Yangda Song, +10 authors, Jinzhang Chen.
Front Immunol, 2021 Jan 26; 11. PMID: 33488622    Free PMC article.
Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!
Boris Guiu, Eric Assenat.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490205    Free PMC article.
Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure.
Khashayar Farsad, Nima Nabavizadeh, +3 authors, Kenneth J Kolbeck.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490212    Free PMC article.
Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
Silvia Catanese, Florian Lordick.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490213    Free PMC article.
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Josep M Llovet, Thierry De Baere, +4 authors, Riccardo Lencioni.
Nat Rev Gastroenterol Hepatol, 2021 Jan 30; 18(5). PMID: 33510460
Review.
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou.
Cell Mol Immunol, 2020 Nov 13; 18(2). PMID: 33177696    Free PMC article.
Review.
The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Lin Liu, Shukui Qin, Yu Zhang.
Target Oncol, 2021 Feb 03; 16(2). PMID: 33528759
Review.
Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
Kyo Sasaki, Sohji Nishina, +5 authors, Keisuke Hino.
Cell Mol Gastroenterol Hepatol, 2020 Nov 17; 11(3). PMID: 33191170    Free PMC article.
A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer.
Takaaki Masuda, Atsushi Nonami, +3 authors, Koshi Mimori.
Breast J, 2020 Dec 06; 26(12). PMID: 33277749    Free PMC article.
Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities.
Cyrill Wehling, Michael T Dill, +11 authors, Markus Mieth.
J Cancer Res Clin Oncol, 2021 Feb 05; 147(8). PMID: 33537908    Free PMC article.
Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
Gen-Sheng Feng, Kaisa L Hanley, Yan Liang, Xiaoxue Lin.
Hepatology, 2020 Jul 28; 73 Suppl 1. PMID: 32715491    Free PMC article.
Review.
Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma.
Kirk J Wangensteen, Kyong-Mi Chang.
Hepatology, 2020 Aug 02; 73 Suppl 1. PMID: 32737895    Free PMC article.
Review.
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Howard Lim, Ravi Ramjeesingh, +4 authors, Brandon M Meyers.
J Natl Cancer Inst, 2020 Sep 09; 113(2). PMID: 32898239    Free PMC article.
Systematic Review.
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Xiaomeng Dai, Yixuan Guo, +9 authors, Weijia Fang.
Theranostics, 2021 Feb 05; 11(7). PMID: 33537099    Free PMC article.
Review.
A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.
Kim A Reiss, Max M Wattenberg, +14 authors, Edgar Ben-Josef.
Mol Cancer Ther, 2020 Dec 04; 20(2). PMID: 33268571    Free PMC article.
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma.
Josep Corominas, Victor Sapena, +11 authors, María Reig.
Cancers (Basel), 2021 Jan 28; 13(3). PMID: 33498698    Free PMC article.
Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis.
Fausto Meriggi, Massimo Graffeo.
Cancers (Basel), 2021 Feb 06; 13(3). PMID: 33540870    Free PMC article.
Review.
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades.
Jun-Yan Li, Yu-Pei Chen, +2 authors, Jun Ma.
Mol Cancer, 2021 Feb 06; 20(1). PMID: 33541368    Free PMC article.
Review.
Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management.
Zaoqu Liu, Long Liu, +4 authors, Xinwei Han.
J Oncol, 2021 Feb 09; 2021. PMID: 33552157    Free PMC article.
Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma.
Gabriella Aitcheson, Anjana Pillai, Bassam Dahman, Binu V John.
Curr Hepatol Rep, 2021 Feb 09; 20(1). PMID: 33552839    Free PMC article.
Review.
Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma.
Ping Tao, Liang Hong, +5 authors, Ruyi Xue.
Front Oncol, 2021 Feb 09; 10. PMID: 33552954    Free PMC article.
Development and External Validation of a Novel Immune Checkpoint-Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma.
Enfa Zhao, Shimin Chen, Ying Dang.
Front Mol Biosci, 2021 Feb 09; 7. PMID: 33553243    Free PMC article.
Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers.
Sandi A Kwee, Maarit Tiirikainen.
Hepatoma Res, 2021 Feb 09; 7. PMID: 33553649    Free PMC article.
Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma.
Kevin P Labadie, Andrew D Ludwig, +12 authors, James O Park.
Sci Rep, 2021 Feb 14; 11(1). PMID: 33580090    Free PMC article.
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Deborah Blythe Doroshow, Sheena Bhalla, +7 authors, Fred R Hirsch.
Nat Rev Clin Oncol, 2021 Feb 14; 18(6). PMID: 33580222
Review.
MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.
Chi Ma, Qianfei Zhang, Tim F Greten.
Cell Immunol, 2021 Jan 29; 361. PMID: 33508529    Free PMC article.
Review.
Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.
Jingyi Zhou, Weiyu Wang, Qi Li.
J Exp Clin Cancer Res, 2021 Feb 19; 40(1). PMID: 33596985    Free PMC article.
Review.
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, +9 authors, Thomas Yau.
J Immunother Cancer, 2021 Feb 11; 9(2). PMID: 33563773    Free PMC article.
Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study.
Zhicheng Jin, Li Chen, +9 authors, Gaojun Teng.
Transl Oncol, 2021 Feb 11; 14(4). PMID: 33567388    Free PMC article.
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tianyu Tang, Xing Huang, +3 authors, Tingbo Liang.
Signal Transduct Target Ther, 2021 Feb 21; 6(1). PMID: 33608497    Free PMC article.
Review.
Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
Haichuan Wang, Pan Wang, +6 authors, Xin Chen.
Cell Death Dis, 2021 Feb 21; 12(2). PMID: 33608500    Free PMC article.
Emerging paradigms in metastasis research.
Ashik Ahmed Abdul Pari, Mahak Singhal, Hellmut G Augustin.
J Exp Med, 2021 Feb 19; 218(1). PMID: 33601416    Free PMC article.
Review.
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors.
Yuan Wei, Xiao Xiao, +2 authors, Dong-Ming Kuang.
Cell Mol Life Sci, 2020 Sep 18; 78(3). PMID: 32940722
Review.
Checkpoint Inhibitors and Hepatotoxicity.
Stephen D H Malnick, Ali Abdullah, Manuela G Neuman.
Biomedicines, 2021 Jan 27; 9(2). PMID: 33494227    Free PMC article.
Review.
Subsequent Ultrasound Vascular Targeting Therapy of Hepatocellular Carcinoma Improves the Treatment Efficacy.
Laith R Sultan, Mrigendra B Karmacharya, +2 authors, Chandra M Sehgal.
Biology (Basel), 2021 Jan 28; 10(2). PMID: 33499069    Free PMC article.
Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis.
Zhaobing Ding, Russell E Ericksen, Qian Yi Lee, Weiping Han.
Amino Acids, 2021 Mar 02; 53(12). PMID: 33646427
Review.
Management of Non-Colorectal Digestive Cancers with Microsatellite Instability.
Mojun Zhu, Zhaohui Jin, Joleen M Hubbard.
Cancers (Basel), 2021 Feb 11; 13(4). PMID: 33561950    Free PMC article.
Review.
Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy.
Kei Moriya, Tadashi Namisaki, +10 authors, Hitoshi Yoshiji.
J Clin Med, 2021 Feb 11; 10(4). PMID: 33562238    Free PMC article.
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Hideki Iwamoto, Takashi Niizeki, +38 authors, Kurume Liver Cancer Study Group Of Japan.
Cancers (Basel), 2021 Feb 11; 13(4). PMID: 33562793    Free PMC article.
Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine.
Hashem O Alsaab, Alanoud S Al-Hibs, +5 authors, Yusuf S Althobaiti.
Int J Mol Sci, 2021 Feb 11; 22(4). PMID: 33562829    Free PMC article.
Review.
Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma.
Moritz Peiseler, Frank Tacke.
Cancers (Basel), 2021 Feb 14; 13(4). PMID: 33578800    Free PMC article.
Review.
Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma.
Aldo Prawira, Thi Bich Uyen Le, Thanh Chung Vu, Hung Huynh.
Liver Int, 2020 Nov 13; 41(3). PMID: 33179425    Free PMC article.
Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature.
Lawrence Kasherman, Jeffrey Doi, +4 authors, Amit M Oza.
Curr Oncol, 2021 Jan 28; 28(1). PMID: 33499164    Free PMC article.
Review.
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
Maria Reig, Peter R Galle, +9 authors, Andrew X Zhu.
Liver Int, 2020 Nov 15; 41(3). PMID: 33188713    Free PMC article.
Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Haichuan Wang, Jingxiao Wang, +14 authors, Xin Chen.
Cell Mol Gastroenterol Hepatol, 2020 Nov 25; 11(4). PMID: 33232824    Free PMC article.
Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
Wei Yuan, Ran Tao, +3 authors, Qin Ning.
Aging (Albany NY), 2021 Jan 27; 13(3). PMID: 33495404    Free PMC article.
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.
Julianne D Twomey, Baolin Zhang.
AAPS J, 2021 Mar 08; 23(2). PMID: 33677681    Free PMC article.
Review.
Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment.
Mariam Mroweh, Gaël Roth, +3 authors, Zuzana Macek Jílková.
Int J Mol Sci, 2021 Mar 07; 22(4). PMID: 33670268    Free PMC article.
Review.
Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years.
Andreas Koulouris, Christos Tsagkaris, Michail Nikolaou.
Toxins (Basel), 2021 Mar 07; 13(2). PMID: 33672017    Free PMC article.
Review.
Beyond immune checkpoint blockade: emerging immunological strategies.
Shawn P Kubli, Thorsten Berger, +2 authors, Tak W Mak.
Nat Rev Drug Discov, 2021 Mar 10; 20(12). PMID: 33686237
Review.
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Dan Su, Bin Wu, Lizheng Shi.
JAMA Netw Open, 2021 Feb 25; 4(2). PMID: 33625508    Free PMC article.
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Taku Shigesawa, Goki Suda, +16 authors, Naoya Sakamoto.
PLoS One, 2021 Mar 02; 16(3). PMID: 33647018    Free PMC article.
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.
Alberto Carretero-González, Irene Otero, +3 authors, Guillermo de Velasco.
Oncoimmunology, 2021 Mar 09; 10(1). PMID: 33680572    Free PMC article.
Systematic Review.
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC.
Roniel Cabrera, Amit G Singal, +11 authors, Adrian M Di Bisceglie.
Hepatol Commun, 2021 Mar 09; 5(3). PMID: 33681685    Free PMC article.
Targeting Angiogenesis for Advanced Hepatocellular Carcinoma.
Yuji Eso.
Intern Med, 2020 Sep 24; 60(3). PMID: 32963171    Free PMC article.
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Tania Afroj, Atsushi Mitsuhashi, +11 authors, Yasuhiko Nishioka.
J Immunol, 2021 Jan 29; 206(6). PMID: 33504617    Free PMC article.
Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy.
Deniz Can Guven, Melek Seren Aksun, +11 authors, Mustafa Erman.
Support Care Cancer, 2021 Mar 13; 29(9). PMID: 33709186
Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.
Hao Wang, Wei Hou, +12 authors, Wei Qiu.
Cell Rep, 2021 Feb 25; 34(8). PMID: 33626345    Free PMC article.
Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2021 Mar 13; 10(1). PMID: 33708635    Free PMC article.
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Chi-Leung Chiang, Sik-Kwan Chan, Shing-Fung Lee, Horace Cheuk-Wai Choi.
Cancers (Basel), 2021 Mar 07; 13(5). PMID: 33668100    Free PMC article.
Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging.
Nao Nagai, Yotaro Kudo, +2 authors, Koji Taniguchi.
Int J Mol Sci, 2021 Mar 07; 22(5). PMID: 33668122    Free PMC article.
Review.
Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients.
Pramod Gaudel, Ghulam Rehman Mohyuddin, January Fields-Meehan.
Fed Pract, 2021 Mar 16; 38(2). PMID: 33716486    Free PMC article.
Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model.
Michal Mauda-Havakuk, Andrew S Mikhail, +12 authors, William F Pritchard.
J Hepatocell Carcinoma, 2021 Mar 18; 8. PMID: 33728278    Free PMC article.
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
Ali Al Zahrani, Ali Alfakeeh.
J Med Case Rep, 2021 Mar 17; 15(1). PMID: 33722275    Free PMC article.
Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.
Jiting Wang, Jun Li, +3 authors, Yaling Li.
Oncol Lett, 2021 Mar 19; 21(4). PMID: 33732355    Free PMC article.
Review.
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis.
Cheng Huang, Xiao-Dong Zhu, +8 authors, Hui-Chuan Sun.
Biomark Res, 2021 Mar 22; 9(1). PMID: 33743822    Free PMC article.
Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.
Camila C Simoes, Swan N Thung, +3 authors, Stephen C Ward.
Mod Pathol, 2020 Sep 30; 34(4). PMID: 32989224
Angiodiversity and organotypic functions of sinusoidal endothelial cells.
Philipp-Sebastian Koch, Ki Hong Lee, Sergij Goerdt, Hellmut G Augustin.
Angiogenesis, 2021 Mar 22; 24(2). PMID: 33745018    Free PMC article.
Review.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Dominik Pfister, Nicolás Gonzalo Núñez, +107 authors, Mathias Heikenwalder.
Nature, 2021 Mar 26; 592(7854). PMID: 33762733    Free PMC article.
Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.
Maria Tampaki, George Vasileios Papatheodoridis, Evangelos Cholongitas.
Clin J Gastroenterol, 2021 Mar 29; 14(3). PMID: 33774785
Review.
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Kuimin Mei, Shukui Qin, +3 authors, Jianjun Zou.
J Immunother Cancer, 2021 Mar 21; 9(3). PMID: 33741732    Free PMC article.
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
Da-Liang Ou, Chia-Wei Chen, +6 authors, Chiun Hsu.
J Immunother Cancer, 2021 Mar 24; 9(3). PMID: 33753566    Free PMC article.
Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma.
Byung Min Lee, Jinsil Seong.
World J Gastroenterol, 2021 Mar 30; 27(10). PMID: 33776363    Free PMC article.
Review.
Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series.
Richard T Lee, Peiying Yang, +5 authors, Ahmed Kaseb.
Case Rep Oncol, 2021 Mar 30; 14(1). PMID: 33776708    Free PMC article.
Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al.
Dimitrios C Ziogas, Helen Gogas.
J Immunother Cancer, 2021 Mar 20; 9(3). PMID: 33737346    Free PMC article.
Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).
Yihe Yan, Leting Zheng, +4 authors, David A Geller.
Cancer Lett, 2021 Mar 11; 506. PMID: 33689775    Free PMC article.
Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Rohini Sharma, Leila Motedayen Aval.
Front Immunol, 2021 Apr 02; 12. PMID: 33790915    Free PMC article.
Review.
The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma.
Fang Wang, Greg Malnassy, Wei Qiu.
Front Oncol, 2021 Apr 02; 11. PMID: 33791228    Free PMC article.
Review.
Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials.
Robin Park, Laercio Lopes da Silva, +4 authors, Anwaar Saeed.
J Hepatocell Carcinoma, 2021 Apr 02; 8. PMID: 33791250    Free PMC article.
Review.
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
Julie Giraud, Domitille Chalopin, Jean-Frédéric Blanc, Maya Saleh.
Front Immunol, 2021 Apr 06; 12. PMID: 33815418    Free PMC article.
Review.
Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study).
Thomas B Brunner, Dominik Bettinger, +13 authors, Eleni Gkika.
Front Oncol, 2021 Apr 06; 11. PMID: 33816309    Free PMC article.
Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration.
Yiping Zou, Zhihong Chen, +8 authors, Haosheng Jin.
Front Mol Biosci, 2021 Apr 06; 8. PMID: 33816550    Free PMC article.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Thomas Decaens, Carlo Barone, +14 authors, Sandrine Faivre.
Br J Cancer, 2021 Apr 08; 125(2). PMID: 33824476    Free PMC article.
How to Treat Hepatocellular Carcinoma in Elderly Patients.
Piera Federico, Emilio Francesco Giunta, +6 authors, Bruno Daniele.
Pharmaceuticals (Basel), 2021 Apr 04; 14(3). PMID: 33800217    Free PMC article.
Review.
Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
Sandra García-Mulero, Maria Henar Alonso, +2 authors, Josep M Piulats.
Int J Mol Sci, 2021 Apr 04; 22(5). PMID: 33800878    Free PMC article.
CD8+ T Cell Responses during HCV Infection and HCC.
Maike Hofmann, Catrin Tauber, Nina Hensel, Robert Thimme.
J Clin Med, 2021 Apr 04; 10(5). PMID: 33801203    Free PMC article.
Review.
Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
I-Tsu Chyuan, Ching-Liang Chu, Ping-Ning Hsu.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33801815    Free PMC article.
Review.
Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs.
Catia Giovannini, Francesca Fornari, Fabio Piscaglia, Laura Gramantieri.
Cells, 2021 Apr 04; 10(3). PMID: 33804511    Free PMC article.
Review.
Resistance to Molecularly Targeted Therapies in Melanoma.
Meet Patel, Adam Eckburg, +4 authors, Neelu Puri.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33807778    Free PMC article.
Review.
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges.
Antonio D'Alessio, Maria Giuseppina Prete, +2 authors, Lorenza Rimassa.
J Hepatocell Carcinoma, 2021 Apr 08; 8. PMID: 33824862    Free PMC article.
Review.
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
Daniel Q Huang, Mark D Muthiah, +13 authors, Yock Young Dan.
Cell Mol Gastroenterol Hepatol, 2020 Dec 20; 11(5). PMID: 33340714    Free PMC article.
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.
Zowi R Huinen, Elisabeth J M Huijbers, +2 authors, Arjan W Griffioen.
Nat Rev Clin Oncol, 2021 Apr 10; 18(8). PMID: 33833434
Review.
Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Jamal Majidpoor, Keywan Mortezaee.
Cell Oncol (Dordr), 2021 Apr 10; 44(4). PMID: 33835425
Review.
Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Stine Karlsen Oversoe, Michelle Simone Clement, +4 authors, Jens Kelsen.
BMC Cancer, 2021 Apr 09; 21(1). PMID: 33827453    Free PMC article.
Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future.
Matthias Ocker, Christian Mayr, +2 authors, Daniel Neureiter.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33805268    Free PMC article.
Review.
Immunotherapy in Advanced Biliary Tract Cancers.
Alice Boilève, Marc Hilmi, +3 authors, David Malka.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33805461    Free PMC article.
Review.
Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma.
Hao-Chien Hung, Jin-Chiao Lee, +7 authors, Wei-Chen Lee.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33807219    Free PMC article.
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Jen-Shin Song, Chih-Chun Chang, +14 authors, Yunching Chen.
Proc Natl Acad Sci U S A, 2021 Mar 24; 118(13). PMID: 33753481    Free PMC article.
Advances in immunotherapy for hepatocellular carcinoma.
Bruno Sangro, Pablo Sarobe, Sandra Hervás-Stubbs, Ignacio Melero.
Nat Rev Gastroenterol Hepatol, 2021 Apr 15; 18(8). PMID: 33850328    Free PMC article.
Review.
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Morgane Bourhis, Juliette Palle, Isabelle Galy-Fauroux, Magali Terme.
Front Immunol, 2021 Apr 16; 12. PMID: 33854498    Free PMC article.
Review.
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma.
Min-Ke He, Run-Bin Liang, +11 authors, Ming Shi.
Ther Adv Med Oncol, 2021 Apr 16; 13. PMID: 33854567    Free PMC article.
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma.
Junjie Ao, Tetsuhiro Chiba, +26 authors, Naoya Kato.
J Cancer, 2021 Apr 16; 12(9). PMID: 33854629    Free PMC article.
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects.
Cheng Zhong, Yirun Li, +5 authors, Hui Lin.
Front Oncol, 2021 Apr 16; 11. PMID: 33854960    Free PMC article.
Review.
NAFLD-Associated HCC: Progress and Opportunities.
Daniel Geh, Quentin M Anstee, Helen L Reeves.
J Hepatocell Carcinoma, 2021 Apr 16; 8. PMID: 33854987    Free PMC article.
Review.
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
Raphael Mohr, Fabian Jost-Brinkmann, +7 authors, Christoph Roderburg.
Front Immunol, 2021 Apr 17; 12. PMID: 33859646    Free PMC article.
Review.
Turning cold tumors into hot tumors by improving T-cell infiltration.
Yuan-Tong Liu, Zhi-Jun Sun.
Theranostics, 2021 Apr 17; 11(11). PMID: 33859752    Free PMC article.
Review.
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Norifumi Iseda, Shinji Itoh, +7 authors, Masaki Mori.
Hepatol Commun, 2021 Apr 17; 5(4). PMID: 33860125    Free PMC article.
Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention.
Joseph H Yacoub, David Mauro, +5 authors, Lauren M B Burke.
Abdom Radiol (NY), 2021 Apr 18; 46(8). PMID: 33864107
Review.
MR-Guided Radiotherapy for Liver Malignancies.
Luca Boldrini, Stefanie Corradini, +4 authors, Laura Dawson.
Front Oncol, 2021 Apr 20; 11. PMID: 33869001    Free PMC article.
Review.
Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.
Songporn Oranratnachai, Sasivimol Rattanasiri, +4 authors, Ammarin Thakkinstian.
Front Oncol, 2021 Apr 20; 11. PMID: 33869060    Free PMC article.
Systematic Review.
Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection.
Jiashuo Chao, Qi Zhu, +6 authors, Hongcheng Sun.
Front Oncol, 2021 Apr 20; 11. PMID: 33869071    Free PMC article.
The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.
Norikazu Une, Mayumi Takano-Kasuya, +10 authors, Kohsuke Gonda.
Med Oncol, 2021 Apr 22; 38(6). PMID: 33881631
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects.
Takuji Torimura, Hideki Iwamoto.
Clin Mol Hepatol, 2020 Dec 16; 27(2). PMID: 33317248    Free PMC article.
Review.
Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside.
Ming-Cheng Guan, Ming-Da Wang, +8 authors, Tian Yang.
World J Gastrointest Oncol, 2021 Apr 24; 13(4). PMID: 33889272    Free PMC article.
Review.
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Sojung Han, Hye Jin Choi, +12 authors, Beom Kyung Kim.
J Cancer Res Clin Oncol, 2021 Apr 25; 147(10). PMID: 33893539
Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
Takuma Nakatsuka, Hayato Nakagawa, +14 authors, Kazuhiko Koike.
J Gastroenterol, 2021 Mar 14; 56(5). PMID: 33712873
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Xin Zhang, Jingjing Wang, +3 authors, Wenjun Wang.
JAMA Netw Open, 2021 Apr 08; 4(4). PMID: 33825837    Free PMC article.
Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
Qin He, Wenjie Huang, +8 authors, Limin Xia.
Theranostics, 2021 Apr 27; 11(12). PMID: 33897880    Free PMC article.
Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?
Ti Zhang, Philippe Merle, +2 authors, Masatoshi Kudo.
Hepatobiliary Surg Nutr, 2021 Apr 27; 10(2). PMID: 33898559    Free PMC article.
Review.
Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective.
Masatoshi Kudo.
Hepatobiliary Surg Nutr, 2021 Apr 27; 10(2). PMID: 33898567    Free PMC article.
Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma.
Thomas Mohr, Sonja Katz, +2 authors, Alexander Tolios.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33917186    Free PMC article.
Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients.
Wei Teng, Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Su.
Cancers (Basel), 2021 May 01; 13(7). PMID: 33917345    Free PMC article.
Review.
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.
Yawen Dong, Jeffrey Sum Lung Wong, +7 authors, Thomas Yau.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33919570    Free PMC article.
Review.
β-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy.
Yekaterina Krutsenko, Aatur D Singhi, Satdarshan P Monga.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33921282    Free PMC article.
Review.
Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer.
Fabrizio Marcucci, Cristiano Rumio.
Cells, 2021 May 01; 10(4). PMID: 33921301    Free PMC article.
Review.
The Current Landscape of Clinical Trials for Systemic Treatment of HCC.
Friedrich Foerster, Peter Robert Galle.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33921731    Free PMC article.
Review.
Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Mirjam B Zeisel, Francesca Guerrieri, Massimo Levrero.
J Clin Med, 2021 May 01; 10(8). PMID: 33923385    Free PMC article.
Review.
Palliating Symptoms in Patients With Hepatocellular Carcinoma Involving the Inferior Vena Cava With External Beam Radiation Therapy.
Peter Cooke, Kunal K Sindhu, +3 authors, Michael Buckstein.
Cureus, 2021 May 01; 13(3). PMID: 33927921    Free PMC article.
Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development.
Xin Li, Yaxi Wang, Xin Ye, Ping Liang.
Front Mol Biosci, 2021 May 01; 8. PMID: 33928118    Free PMC article.
Review.
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
Runze Shang, Xinhua Song, +12 authors, Xin Chen.
Gut, 2020 Nov 05; 70(9). PMID: 33144318    Free PMC article.
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Takuji Okusaka, Kenji Ikeda, +17 authors, Hiromitsu Kumada.
J Gastroenterol, 2021 May 06; 56(6). PMID: 33948712    Free PMC article.
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
James J Harding, Richard K Do, +7 authors, Ghassan K Abou-Alfa.
Cancer Med, 2021 Apr 04; 10(9). PMID: 33811482    Free PMC article.
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Baek-Yeol Ryoo, Ann-Li Cheng, +13 authors, Shukui Qin.
Br J Cancer, 2021 May 12; 125(2). PMID: 33972742    Free PMC article.
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study.
Chia-Chi Lin, Tsai-Sheng Yang, +3 authors, Chiun Hsu.
Oncologist, 2020 Oct 06; 25(12). PMID: 33017497    Free PMC article.
Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit.
J J X Lee, D W-M Tai, S P Choo.
ESMO Open, 2021 Apr 23; 6(3). PMID: 33887687    Free PMC article.
Review.
Congenital heart disease-associated liver disease: a narrative review.
Florian P Reiter, Nino J Hadjamu, +5 authors, Gerald Denk.
Cardiovasc Diagn Ther, 2021 May 11; 11(2). PMID: 33968635    Free PMC article.
Review.
Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
Hui Li, Shukui Qin, +8 authors, Jianjun Zou.
Drug Des Devel Ther, 2021 May 13; 15. PMID: 33976538    Free PMC article.
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.
Masatoshi Kudo.
Liver Cancer, 2021 May 13; 10(2). PMID: 33977086    Free PMC article.
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
Changhoon Yoo, Jwa Hoon Kim, +10 authors, Baek-Yeol Ryoo.
Liver Cancer, 2021 May 13; 10(2). PMID: 33977087    Free PMC article.
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
Atsushi Hiraoka, Takashi Kumada, +30 authors, Masatoshi Kudo.
Liver Cancer, 2021 May 13; 10(2). PMID: 33977088    Free PMC article.
Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein.
Yumi Kosaka, Tomoki Kimura, +21 authors, Hiroshi Aikata.
Liver Cancer, 2021 May 13; 10(2). PMID: 33977091    Free PMC article.
Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers.
Katherine E Lindblad, Marina Ruiz de Galarreta, Amaia Lujambio.
Front Immunol, 2021 May 14; 12. PMID: 33981303    Free PMC article.
Review.
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.
Jeffrey Sum-Lung Wong, Yawen Dong, +14 authors, Thomas Yau.
Cancers (Basel), 2021 May 01; 13(9). PMID: 33919277    Free PMC article.
Advances in Targeting Cutaneous Melanoma.
Dimitri Kasakovski, Marina Skrygan, Thilo Gambichler, Laura Susok.
Cancers (Basel), 2021 May 01; 13(9). PMID: 33925915    Free PMC article.
Review.
Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
Diyang Xie, Qiman Sun, +4 authors, Qiang Gao.
Ann Transl Med, 2021 May 15; 9(8). PMID: 33987350    Free PMC article.
Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers.
Christine Koch, Markus Göller, +9 authors, Jörg Trojan.
Cancers (Basel), 2021 May 01; 13(9). PMID: 33924810    Free PMC article.
Immunotherapy Updates in Advanced Hepatocellular Carcinoma.
Amisha Singh, Ryan J Beechinor, +6 authors, May Cho.
Cancers (Basel), 2021 May 06; 13(9). PMID: 33946408    Free PMC article.
Review.
New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy.
Anil C Anand, Subrat K Acharya.
J Clin Exp Hepatol, 2021 May 18; 11(3). PMID: 33994710    Free PMC article.
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Amber G Bozward, Frazer Warricker, Ye H Oo, Salim I Khakoo.
Front Immunol, 2021 May 18; 12. PMID: 33995362    Free PMC article.
Review.
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.
Tomi Jun, Umut Ozbek, +22 authors, Celina Ang.
Ther Adv Med Oncol, 2021 May 18; 13. PMID: 33995594    Free PMC article.
The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
Aline Mähringer-Kunz, Verena Steinle, +8 authors, Arndt Weinmann.
PLoS One, 2021 May 08; 16(5). PMID: 33961627    Free PMC article.
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
Xiang-Yuan Luo, Kong-Ming Wu, Xing-Xing He.
J Exp Clin Cancer Res, 2021 May 20; 40(1). PMID: 34006331    Free PMC article.
Review.
Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches.
Renumathy Dhanasekaran.
Semin Liver Dis, 2021 Mar 26; 41(1). PMID: 33764481    Free PMC article.
Review.
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma.
Laura Gramantieri, Catia Giovannini, Fabio Piscaglia, Francesca Fornari.
J Hepatocell Carcinoma, 2021 May 21; 8. PMID: 34012928    Free PMC article.
Review.
Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options.
Andreas Koulouris, Christos Tsagkaris, +3 authors, Michail Nikolaou.
J Hepatocell Carcinoma, 2021 May 21; 8. PMID: 34012929    Free PMC article.
Review.
Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide.
Lukas Müller, Fabian Stoehr, +3 authors, Roman Kloeckner.
J Hepatocell Carcinoma, 2021 May 21; 8. PMID: 34012930    Free PMC article.
Review.
NDRG2 inhibition facilitates angiogenesis of hepatocellular carcinoma.
Jianlong Wang, Tao Li, +3 authors, Jiansheng Kang.
Open Med (Wars), 2021 May 21; 16(1). PMID: 34013046    Free PMC article.
The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma.
Lunxu Li, Shilin Xia, +2 authors, Dong Shang.
Sci Rep, 2021 May 23; 11(1). PMID: 34021184    Free PMC article.
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
Xu Yang, Ying Hu, +17 authors, Haitao Zhao.
J Immunother Cancer, 2021 May 12; 9(5). PMID: 33972389    Free PMC article.
In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma.
Isabella Lurje, Wiebke Werner, +3 authors, Linda Hammerich.
Front Immunol, 2021 May 25; 12. PMID: 34025657    Free PMC article.
Review.
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Yue Han, Wei-Hua Zhi, +3 authors, Jian-Feng Luo.
World J Gastroenterol, 2021 May 28; 27(19). PMID: 34040331    Free PMC article.
The two facets of gp130 signalling in liver tumorigenesis.
Dirk Schmidt-Arras, Eithan Galun, Stefan Rose-John.
Semin Immunopathol, 2021 May 29; 43(4). PMID: 34047814    Free PMC article.
Review.
Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus.
John R Bergquist, Amy Y Li, +3 authors, Brendan C Visser.
Dig Dis Sci, 2020 Nov 04; 66(6). PMID: 33140182
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.
Amit G Singal, Yujin Hoshida, +12 authors, Augusto Villanueva.
Gastroenterology, 2021 Mar 12; 160(7). PMID: 33705745    Free PMC article.
Indian Council of Medical Research consensus document on hepatocellular carcinoma.
Bhawna Sirohi, Shailesh V Shrikhande, +13 authors, Indian Council of Medical Research Guidelines Working Group.
Indian J Med Res, 2021 Mar 13; 152(5). PMID: 33707388    Free PMC article.
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development.
Kenji Hashimoto.
Cancers (Basel), 2021 Jun 03; 13(10). PMID: 34064598    Free PMC article.
Review.
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
Patrizia Leone, Antonio Giovanni Solimando, +7 authors, Vito Racanelli.
Vaccines (Basel), 2021 Jun 03; 9(5). PMID: 34065489    Free PMC article.
Review.
Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma.
Issei Saeki, Takahiro Yamasaki, +13 authors, Isao Sakaida.
Cancers (Basel), 2021 Jun 03; 13(9). PMID: 34067075    Free PMC article.
Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance.
Sheng-Han Wang, Shiou-Hwei Yeh, Pei-Jer Chen.
Cancers (Basel), 2021 Jun 03; 13(10). PMID: 34070067    Free PMC article.
Review.
Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Fuqun Wei, Qizhen Huang, +2 authors, Yongyi Zeng.
Cancer Manag Res, 2021 Jun 04; 13. PMID: 34079375    Free PMC article.
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.
Alessandro Granito, Sara Marinelli, +4 authors, Francesco Tovoli.
J Hepatocell Carcinoma, 2021 Jun 04; 8. PMID: 34079777    Free PMC article.
Review.
Developments in Hepatocellular Cancer Treatment.
Bridget O'Brien.
J Adv Pract Oncol, 2021 Jun 05; 12(3). PMID: 34084581    Free PMC article.
Development of Immunotherapy Combination Strategies in Cancer.
Timothy A Yap, Eileen E Parkes, +3 authors, Hussein A Tawbi.
Cancer Discov, 2021 Apr 04; 11(6). PMID: 33811048    Free PMC article.
Review.
Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma.
Wei Teng, Chen-Chun Lin, +4 authors, Shi-Ming Lin.
Am J Cancer Res, 2021 Jun 08; 11(5). PMID: 34094688    Free PMC article.
Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma.
Liting Zhong, Dehua Wu, +4 authors, Yuli Wang.
Front Oncol, 2021 Jun 08; 11. PMID: 34094988    Free PMC article.
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Giovanni Melillo, Vikram Chand, +2 authors, Cristian Massacesi.
Adv Ther, 2021 Apr 22; 38(6). PMID: 33881745    Free PMC article.
Review.
Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma.
Aliya Qayyum, Priya Bhosale, +8 authors, Ahmed O Kaseb.
Abdom Radiol (NY), 2020 Sep 26; 46(3). PMID: 32974761    Free PMC article.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N Moore, Michael Bookman, +25 authors, Sandro Pignata.
J Clin Oncol, 2021 Apr 24; 39(17). PMID: 33891472    Free PMC article.
Experience with regorafenib in the treatment of hepatocellular carcinoma.
Alessandro Granito, Antonella Forgione, +6 authors, Francesco Tovoli.
Therap Adv Gastroenterol, 2021 Jun 10; 14. PMID: 34104211    Free PMC article.
Review.
Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.
Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu, Jiang Chen.
Ther Adv Med Oncol, 2021 Jun 10; 13. PMID: 34104226    Free PMC article.
Review.
Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma.
Cecilia Monge, Changqing Xie, Seth M Steinberg, Tim F Greten.
J Hepatocell Carcinoma, 2021 Jun 10; 8. PMID: 34104639    Free PMC article.
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.
Massimiliano Cadamuro, Alberto Lasagni, +9 authors, Luca Fabris.
Expert Opin Investig Drugs, 2021 Feb 25; 30(4). PMID: 33622120    Free PMC article.
Review.
A new perspective on the immune escape mechanism in HCC: onco-foetal reprogramming.
Sin Chi Chew, Si Ying Choo, Pierce Kah-Hoe Chow.
Br J Cancer, 2021 Mar 27; 124(12). PMID: 33767421    Free PMC article.
Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion.
Kai Zhang, Changcheng Tao, +3 authors, Weiqi Rong.
Int J Gen Med, 2021 Jun 12; 14. PMID: 34113155    Free PMC article.
Hyperthermia and Tumor Immunity.
Ather Adnan, Nina M Muñoz, +3 authors, Rahul A Sheth.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34063752    Free PMC article.
Review.
Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation.
Ancelin Preel, Margaux Hermida, +7 authors, Boris Guiu.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34070800    Free PMC article.
Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?
Alice Boilève, Marc Hilmi, +2 authors, Cindy Neuzillet.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34070929    Free PMC article.
Review.
The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective.
Juan Pablo Unfried, Paloma Sangro, +2 authors, Puri Fortes.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34071216    Free PMC article.
Review.
The Immunotherapy Landscape in Adrenocortical Cancer.
Guillaume J Pegna, Nitin Roper, +5 authors, Jaydira Del Rivero.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34071333    Free PMC article.
Review.
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki.
Int J Mol Sci, 2021 Jun 03; 22(11). PMID: 34071550    Free PMC article.
Review.
Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.
Sadahisa Ogasawara, Su-Pin Choo, +4 authors, Pierce K H Chow.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34071818    Free PMC article.
Review.
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study.
Giovanni Marasco, Francesco Poggioli, +28 authors, On Behalf Of The Italian Liver Cancer Ita Li Ca Group.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34072309    Free PMC article.
Control of Tumor Progression by Angiocrine Factors.
Elisenda Alsina-Sanchis, Ronja Mülfarth, Andreas Fischer.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34073394    Free PMC article.
Review.
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Kaoru Tsuchiya, Masayuki Kurosaki, +24 authors, On Behalf Of Japanese Red Cross Liver Study Group.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34073396    Free PMC article.
The Endless Sources of Hepatocellular Carcinoma Heterogeneity.
Marina Barcena-Varela, Amaia Lujambio.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34073538    Free PMC article.
Review.
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.
Keiko Tanimura, Tadaaki Yamada, +12 authors, Koichi Takayama.
Front Oncol, 2021 Jun 15; 11. PMID: 34123822    Free PMC article.
Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients.
Alessandro Inno, Andrea Chiampan, +3 authors, Stefania Gori.
Front Cardiovasc Med, 2021 Jun 15; 8. PMID: 34124192    Free PMC article.
Review.
The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ioannis A Ziogas, Alexandros P Evangeliou, +7 authors, Georgios Tsoulfas.
Oncologist, 2020 Dec 15; 26(6). PMID: 33314549    Free PMC article.
Systematic Review.
Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma.
Xuequan Wang, Ziming Xing, +2 authors, Tongjing Xing.
Aging (Albany NY), 2021 May 01; 13(10). PMID: 33929972    Free PMC article.
DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression.
Naidong Zhang, Rongping Yin, +13 authors, Yuhui Huang.
Proc Natl Acad Sci U S A, 2021 May 27; 118(22). PMID: 34035167    Free PMC article.
Cellular based treatment modalities for unresectable hepatocellular carcinoma.
Konstantinos Damiris, Hamza Abbad, Nikolaos Pyrsopoulos.
World J Clin Oncol, 2021 Jun 17; 12(5). PMID: 34131562    Free PMC article.
Review.
Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma.
Daniel Wai-Hung Ho, Yu-Man Tsui, +14 authors, Irene Oi-Lin Ng.
Nat Commun, 2021 Jun 19; 12(1). PMID: 34140495    Free PMC article.
Systemic Therapy for Hepatocellular Carcinoma.
Jennifer Wang, Anjana Pillai.
Clin Liver Dis (Hoboken), 2021 Jun 18; 17(5). PMID: 34136138    Free PMC article.
Review.
Radiation Therapies for the Treatment of Hepatocellular Carcinoma.
Neehar D Parikh, Kyle Cuneo, Mishal Mendiratta-Lala.
Clin Liver Dis (Hoboken), 2021 Jun 18; 17(5). PMID: 34136139    Free PMC article.
Review.
Using cell-free DNA for HCC surveillance and prognosis.
Nguyen H Tran, John Kisiel, Lewis R Roberts.
JHEP Rep, 2021 Jun 18; 3(4). PMID: 34136776    Free PMC article.
Review.
Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report.
Li-Fang Bian, Chao Zheng, Xiao-Lan Shi.
World J Clin Cases, 2021 Jun 19; 9(16). PMID: 34141773    Free PMC article.
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma.
Antonella Cammarota, Antonio D'Alessio, +2 authors, Nicola Personeni.
Drugs Aging, 2021 Jun 22; 38(7). PMID: 34152589
Review.
Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
Burcin Özdirik, Fabian Jost-Brinkmann, +5 authors, Tobias Müller.
Medicine (Baltimore), 2021 Jun 16; 100(24). PMID: 34128898    Free PMC article.
Review.
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
Sijia Ren, Xinxin Xiong, +2 authors, Penghui Zhou.
Front Immunol, 2021 Jun 22; 12. PMID: 34149730    Free PMC article.
Review.
Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor.
Aldo Prawira, Thi Bich Uyen Le, Rebecca Zhi Wen Ho, Hung Huynh.
J Cancer Res Clin Oncol, 2021 Jun 23; 147(10). PMID: 34156519    Free PMC article.
TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Binyong Liang, Yi Zhou, +15 authors, Xin Chen.
J Hepatol, 2021 Feb 13; 75(1). PMID: 33577921    Free PMC article.
Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice.
Takayoshi Shirasaki, Kazuhisa Murai, +8 authors, Shuichi Kaneko.
Sci Rep, 2021 Jun 24; 11(1). PMID: 34158541    Free PMC article.
Exploring liver cancer biology through functional genetic screens.
Cun Wang, Ying Cao, +2 authors, Wenxin Qin.
Nat Rev Gastroenterol Hepatol, 2021 Jun 25; 18(10). PMID: 34163045
Review.
Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
Haichuan Wang, Xinhua Song, +17 authors, Xin Chen.
Hepatology, 2020 Dec 29; 74(1). PMID: 33368437    Free PMC article.
Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma.
Hong Zhang, Kristen Spencer, Stephen K Burley, X F Steven Zheng.
Drug Discov Today, 2021 Feb 10; 26(6). PMID: 33561464    Free PMC article.
Review.
Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Sung Won Chung, Min Kyung Park, +15 authors, Jeong-Hoon Lee.
J Hepatocell Carcinoma, 2021 Jun 25; 8. PMID: 34164351    Free PMC article.
Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
Suresh Gopi Kalathil, Yasmin Thanavala.
Cells, 2021 Jun 03; 10(6). PMID: 34071188    Free PMC article.
Review.
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study.
Young Youn Cho, Su Jong Yu, +12 authors, Yoon Jun Kim.
J Hepatocell Carcinoma, 2021 Jun 26; 8. PMID: 34169044    Free PMC article.
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Yasutoshi Fujii, Atsushi Ono, +14 authors, Kazuaki Chayama.
J Exp Clin Cancer Res, 2021 Jun 28; 40(1). PMID: 34174931    Free PMC article.
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.
Hong-Ming Tsai, Meng-Zhi Han, +11 authors, Hsin-Yu Kuo.
Cancer Immunol Immunother, 2021 Jan 08; 70(7). PMID: 33409737    Free PMC article.
Cancer and hepatic steatosis.
R Paternostro, W Sieghart, M Trauner, M Pinter.
ESMO Open, 2021 Jun 18; 6(4). PMID: 34139486    Free PMC article.
Review.
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
I G Rapposelli, S Shimose, +37 authors, A Casadei-Gardini.
ESMO Open, 2021 Jun 19; 6(4). PMID: 34144271    Free PMC article.
Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research.
Francesca Negri, Gabriele Missale, Anna Degli Antoni, Camillo Porta.
Transl Oncol, 2021 Jun 19; 14(9). PMID: 34144349    Free PMC article.
Review.
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.
Zobair M Younossi, Linda Henry.
JHEP Rep, 2021 Jul 01; 3(4). PMID: 34189448    Free PMC article.
Review.
Role of endothelial cells in tumor microenvironment.
Dawei Yang, Peipei Guo, Tianrui He, Charles A Powell.
Clin Transl Med, 2021 Jun 30; 11(6). PMID: 34185401    Free PMC article.
Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies.
Binghan Zhou, Yuan Gao, Peng Zhang, Qian Chu.
Front Immunol, 2021 Jul 02; 12. PMID: 34194441    Free PMC article.
Review.
Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy.
Konstantinos Arvanitakis, Ioannis Mitroulis, Georgios Germanidis.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34200529    Free PMC article.
Review.
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma.
Hyuk Moon, Simon Weonsang Ro.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34204242    Free PMC article.
Review.
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Hideki Iwamoto, Shigeo Shimose, +15 authors, On Behalf Of The Kurume Liver Cancer Study Group Of Japan.
Cancers (Basel), 2021 Jul 03; 13(11). PMID: 34205099    Free PMC article.
Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Anne Dyhl-Polk, Marta Kramer Mikkelsen, Morten Ladekarl, Dorte Lisbet Nielsen.
J Clin Med, 2021 Jul 03; 10(12). PMID: 34208788    Free PMC article.
Review.
Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
Xuqi Sun, Jie Mei, +6 authors, Minshan Chen.
BMC Cancer, 2021 Jul 06; 21(1). PMID: 34218801    Free PMC article.
Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results.
Xavier Adhoute, Edouard Larrey, +11 authors, Marc Bourliere.
World J Clin Cases, 2021 Jul 06; 9(18). PMID: 34222423    Free PMC article.
Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
Brandon Swed, Kara Ryan, +2 authors, Gagandeep Brar.
Medicine (Baltimore), 2021 Jun 24; 100(25). PMID: 34160456    Free PMC article.
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.
Matthias Pinter, Rakesh K Jain, Dan G Duda.
JAMA Oncol, 2020 Oct 23; 7(1). PMID: 33090190    Free PMC article.
Review.
Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers.
Martina Mang Leng Lei, Terence Kin Wah Lee.
Front Cell Dev Biol, 2021 Jul 09; 9. PMID: 34235155    Free PMC article.
Review.
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
Haijing Deng, Anna Kan, +13 authors, Ming Zhao.
J Immunother Cancer, 2021 Jun 26; 9(6). PMID: 34168004    Free PMC article.
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Ester Gonzalez-Sanchez, Javier Vaquero, +6 authors, Isabel Fabregat.
Cancers (Basel), 2021 Jul 03; 13(13). PMID: 34209646    Free PMC article.
Review.
Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
Federico Piñero, Leonardo Gomes da Fonseca.
World J Gastroenterol, 2021 Jul 10; 27(24). PMID: 34239261    Free PMC article.
Review.
Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements.
Abhilash Perisetti, Hemant Goyal, +2 authors, Emmanouil Giorgakis.
World J Gastroenterol, 2021 Jul 10; 27(24). PMID: 34239263    Free PMC article.
Review.
Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update.
Masatoshi Kudo.
Liver Cancer, 2021 Jul 10; 10(3). PMID: 34239807    Free PMC article.
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
Masatoshi Kudo, Yusuke Kawamura, +22 authors, Tetsuo Takehara.
Liver Cancer, 2021 Jul 10; 10(3). PMID: 34239808    Free PMC article.
Review.
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.
Arndt Vogel, Lorenza Rimassa, +10 authors, Philippe Merle.
Liver Cancer, 2021 Jul 10; 10(3). PMID: 34239810    Free PMC article.
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Masatoshi Kudo, Kenta Motomura, +10 authors, Junji Furuse.
Liver Cancer, 2021 Jul 10; 10(3). PMID: 34239811    Free PMC article.
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial.
Masatoshi Kudo, Ho Yeong Lim, +11 authors, Baek-Yeol Ryoo.
Liver Cancer, 2021 Jul 10; 10(3). PMID: 34239813    Free PMC article.
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions.
Francesca Fornari, Catia Giovannini, Fabio Piscaglia, Laura Gramantieri.
J Hepatocell Carcinoma, 2021 Jul 10; 8. PMID: 34239844    Free PMC article.
Review.
Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab.
Yuichi Honma, Michihiko Shibata, +14 authors, Masaru Harada.
Intern Med, 2021 Jan 19; 60(12). PMID: 33456046    Free PMC article.
Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.
Kabir A Khan, Florence Th Wu, William Cruz-Munoz, Robert S Kerbel.
EMBO Mol Med, 2021 Jun 15; 13(7). PMID: 34125494    Free PMC article.
Review.
Irreversible electroporation enhances immunotherapeutic effect in the off-target tumor in a murine model of orthotopic HCC.
Xiaoju Shi, Conor O'Neill, +6 authors, Robert C Martin.
Am J Cancer Res, 2021 Jul 13; 11(6). PMID: 34249464    Free PMC article.
Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Dmitrii Shek, Scott A Read, +4 authors, Golo Ahlenstiel.
Oncologist, 2021 Apr 06; 26(7). PMID: 33818870    Free PMC article.
Review.
Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma.
Ling Li, Gilad Halpert, +19 authors, Florin M Selaru.
JCI Insight, 2021 May 19; 6(12). PMID: 34003798    Free PMC article.
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014.
Aman Opneja, Gino Cioffi, +10 authors, Richard T Lee.
Cancer Med, 2021 Jun 02; 10(13). PMID: 34060249    Free PMC article.
Hepatocellular carcinoma, novel therapies on the horizon.
Imane El Dika, Iman Makki, Ghassan K Abou-Alfa.
Chin Clin Oncol, 2020 Jun 13; 10(1). PMID: 32527116    Free PMC article.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Lakshmi Nayak, Annette M Molinaro, +19 authors, David A Reardon.
Clin Cancer Res, 2020 Nov 18; 27(4). PMID: 33199490    Free PMC article.
Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
Nguyen H Tran, Nathan R Foster, +6 authors, Mitesh J Borad.
Invest New Drugs, 2021 Mar 02; 39(4). PMID: 33646489    Free PMC article.
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.
Álvaro Díaz-González, Víctor Sapena, +14 authors, María Reig.
United European Gastroenterol J, 2021 Jul 07; 9(6). PMID: 34228394    Free PMC article.
Spinal Cord Compression as Initial Presentation in Hepatocellular Carcinoma.
Jasmeet Kaur, Ambreen Malik, Mehrvaan Kaur, Judie Goodman.
Cureus, 2021 Jul 17; 13(7). PMID: 34268063    Free PMC article.
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Toshifumi Tada, Takashi Kumada, +30 authors, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
Sci Rep, 2021 Jul 16; 11(1). PMID: 34262065    Free PMC article.
Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.
Vaia Florou, Sonam Puri, Ignacio Garrido-Laguna, Breelyn A Wilky.
Ann Transl Med, 2021 Jul 20; 9(12). PMID: 34277835    Free PMC article.
Review.
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.
Jingyan Yang, Rongzhe Liu, +2 authors, Ahmed Shelbaya.
Appl Health Econ Health Policy, 2021 Jan 29; 19(4). PMID: 33506318    Free PMC article.
The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.
Sebastian Meltzer, Annette Torgunrud, +12 authors, Anne Hansen Ree.
Br J Cancer, 2021 Apr 11; 125(2). PMID: 33837301    Free PMC article.
Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study.
Yumi Kosaka, Tomokazu Kawaoka, +16 authors, Hiroshi Aikata.
Clin J Gastroenterol, 2021 Jul 23; 14(5). PMID: 34291386
Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma.
Annabelle Vogt, Farsaneh Sadeghlar, +14 authors, Maria A Gonzalez-Carmona.
Cancers (Basel), 2021 Jul 21; 13(13). PMID: 34282787    Free PMC article.
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.
Wuzhen Chen, Lesang Shen, +5 authors, Zhigang Chen.
Biomark Res, 2021 Jul 24; 9(1). PMID: 34294146    Free PMC article.
Review.
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Dmytro Trukhin, Elena Poddubskaya, +17 authors, STELLA Investigators.
BioDrugs, 2021 Apr 30; 35(4). PMID: 33914256    Free PMC article.
Prospects and Challenges for T Cell-Based Therapies of HCC.
Norman Woller, Sophie Anna Engelskircher, Thomas Wirth, Heiner Wedemeyer.
Cells, 2021 Jul 03; 10(7). PMID: 34209393    Free PMC article.
Review.
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.
Yating Zhao, Liu Liu, Liang Weng.
Front Pharmacol, 2021 Jul 27; 12. PMID: 34305619    Free PMC article.
Review.
Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.
Shao-Li Huang, Yu-Ming Wang, +5 authors, Hong-Wu Xin.
Front Genet, 2021 Jul 27; 12. PMID: 34306031    Free PMC article.
Review.
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.
Stephanie Busche, Katharina John, +6 authors, Heike Bantel.
Cell Death Dis, 2021 Jul 28; 12(8). PMID: 34312366    Free PMC article.
Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?
Peter H Goff, Rashmi Bhakuni, +3 authors, Paul Nghiem.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298632    Free PMC article.
Review.
How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
Ming-Huang Chen, Sheng-Nan Lu, +6 authors, Li-Tzong Chen.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298750    Free PMC article.
Review.
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
Akinori Kubo, Goki Suda, +15 authors, Naoya Sakamoto.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298844    Free PMC article.
Updates on the Diagnosis and Management of Hepatocellular Carcinoma.
Aimun Raees, Muhammad Kamran, Hasan Özkan, Wasim Jafri.
Euroasian J Hepatogastroenterol, 2021 Jul 29; 11(1). PMID: 34316462    Free PMC article.
Review.
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Dexi Zhou, Jiajie Luan, Cheng Huang, Jun Li.
Gut Liver, 2020 Oct 23; 15(4). PMID: 33087588    Free PMC article.
Review.
Hepatocellular carcinoma: a clinical and pathological overview.
Salvatore Lorenzo Renne, Samantha Sarcognato, +4 authors, Luca Di Tommaso.
Pathologica, 2021 Jul 24; 113(3). PMID: 34294938    Free PMC article.
Review.
Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic.
Riccardo Inchingolo, Fabrizio Acquafredda, +7 authors, Riccardo Memeo.
World J Gastroenterol, 2021 Jul 30; 27(25). PMID: 34321843    Free PMC article.
Review.
Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma.
Pu Chen, Qiong-Xuan Fang, Dong-Bo Chen, Hong-Song Chen.
World J Gastrointest Oncol, 2021 Jul 30; 13(7). PMID: 34322196    Free PMC article.
Review.
The immunological and metabolic landscape in primary and metastatic liver cancer.
Xin Li, Pierluigi Ramadori, +3 authors, Mathias Heikenwalder.
Nat Rev Cancer, 2021 Jul 31; 21(9). PMID: 34326518
Review.
Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.
Hsuan Yeh, Chung-Cheng Chiang, Tzung-Hai Yen.
World J Gastroenterol, 2021 Jul 31; 27(26). PMID: 34326614    Free PMC article.
Review.
Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis.
Ying He, Rui Xu, Li Peng, Xiaoyu Hu.
PLoS One, 2021 Jul 30; 16(7). PMID: 34324544    Free PMC article.
Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Junyan Tao, Yekaterina Krutsenko, +10 authors, Satdarshan P Monga.
Hepatology, 2021 Feb 03; 74(2). PMID: 33529367    Free PMC article.
Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells.
Kazutaka Iijima, Hajime Nakamura, +7 authors, Junji Kato.
Oncol Lett, 2021 Aug 03; 22(1). PMID: 34335918    Free PMC article.
Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma.
Changchen Jiang, Shenghua Jing, +4 authors, Zetian Shen.
Front Oncol, 2021 Aug 03; 11. PMID: 34336647    Free PMC article.
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma.
Ying-Chun Shen, Pei-Chang Lee, +14 authors, Ann-Lii Cheng.
J Hepatocell Carcinoma, 2021 Aug 03; 8. PMID: 34336726    Free PMC article.
Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Nicole M Nevarez, Adam C Yopp.
J Hepatocell Carcinoma, 2021 Aug 06; 8. PMID: 34350140    Free PMC article.
Review.
The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.
Masaki Kaibori, Hideyuki Matsushima, +5 authors, Mitsugu Sekimoto.
Asian Pac J Cancer Prev, 2021 Apr 29; 22(4). PMID: 33906315    Free PMC article.
Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib.
Michele Manganelli, Ilaria Grossi, +13 authors, Alessandro Salvi.
Biomedicines, 2021 Aug 07; 9(7). PMID: 34356875    Free PMC article.
Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma.
Naoshi Nishida.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359568    Free PMC article.
Review.
The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma.
Chunye Zhang, Ming Yang.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359642    Free PMC article.
Review.
Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma.
Francesca Pezzuto, Francesco Izzo, +5 authors, Maria Lina Tornesello.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359670    Free PMC article.
Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data.
Wing-Lok Chan, Horace Cheuk-Wai Choi, +13 authors, Dora Lai-Wan Kwong.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359698    Free PMC article.
Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma.
Yu-Yun Shao, Nai-Yun Sun, +6 authors, Zhong-Zhe Lin.
Cells, 2021 Aug 08; 10(7). PMID: 34359867    Free PMC article.
Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Sally Temraz, Farah Nassar, +3 authors, Rihab Nasr.
Int J Mol Sci, 2021 Aug 08; 22(15). PMID: 34360566    Free PMC article.
Review.
The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
Youssef Bouferraa, Andrea Chedid, +4 authors, Ali Shamseddine.
Int J Mol Sci, 2021 Aug 08; 22(15). PMID: 34360802    Free PMC article.
Review.
Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting.
Maria Corina Plaz Torres, Quirino Lai, +7 authors, Edoardo G Giannini.
J Clin Med, 2021 Aug 08; 10(15). PMID: 34361985    Free PMC article.
Review.
Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma.
Gwang Hyeon Choi, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong.
World J Gastroenterol, 2021 Aug 10; 27(27). PMID: 34366616    Free PMC article.
Recent advances in gastrointestinal cancers.
Natacha Bordry, Christoforos Astaras, +3 authors, Thibaud Koessler.
World J Gastroenterol, 2021 Aug 10; 27(28). PMID: 34366620    Free PMC article.
Review.
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells.
Caecilia H C Sukowati, Korri Elvanita El-Khobar, Claudio Tiribelli.
World J Stem Cells, 2021 Aug 10; 13(7). PMID: 34367478    Free PMC article.
Review.
Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis.
Hai-Yi Long, Tong-Yi Huang, +2 authors, Bao-Xian Liu.
World J Clin Cases, 2021 Aug 10; 9(21). PMID: 34368295    Free PMC article.
Review.
Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports.
Shao-Ru Liu, Qing Yan, +5 authors, Rui Zhang.
World J Clin Cases, 2021 Aug 10; 9(21). PMID: 34368318    Free PMC article.
Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab.
Chiun Hsu, Lorenza Rimassa, +2 authors, Ahmed O Kaseb.
Ther Adv Med Oncol, 2021 Aug 12; 13. PMID: 34377156    Free PMC article.
Review.
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Stephen P Hack, Wendy Verret, +6 authors, Andrew X Zhu.
Ther Adv Med Oncol, 2021 Aug 12; 13. PMID: 34377158    Free PMC article.
Advances of Targeted Therapy for Hepatocellular Carcinoma.
Mengke Niu, Ming Yi, +2 authors, Kongming Wu.
Front Oncol, 2021 Aug 13; 11. PMID: 34381735    Free PMC article.
Review.
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Aung Naing, Fiona Thistlethwaite, +15 authors, Alexander Spira.
J Immunother Cancer, 2021 Jul 25; 9(7). PMID: 34301809    Free PMC article.
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects.
Antonio D'Alessio, Lorenza Rimassa, Alessio Cortellini, David James Pinato.
J Hepatocell Carcinoma, 2021 Aug 14; 8. PMID: 34386437    Free PMC article.
Review.
SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma.
Zuyi Ma, Zhenchong Li, +10 authors, Baohua Hou.
J Hepatocell Carcinoma, 2021 Aug 17; 8. PMID: 34395329    Free PMC article.
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Guoying Zhou, Patrick P C Boor, +2 authors, Jaap Kwekkeboom.
Br J Cancer, 2021 Aug 18; 126(1). PMID: 34400801    Free PMC article.
Review.
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Atsushi Hiraoka, Takashi Kumada, +31 authors, Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
J Gastroenterol Hepatol, 2020 Nov 11; 36(7). PMID: 33171524    Free PMC article.
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Atsushi Hiraoka, Takashi Kumada, +32 authors, Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
Sci Rep, 2021 Aug 19; 11(1). PMID: 34404856    Free PMC article.
Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study.
Hisanori Muto, Teiji Kuzuya, +5 authors, Mitsuhiro Fujishiro.
Medicine (Baltimore), 2021 Aug 17; 100(31). PMID: 34397843    Free PMC article.
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance.
Yulei Wang, Li-Chun Lu, +4 authors, Chih-Hung Hsu.
Exp Hematol Oncol, 2021 Aug 18; 10(1). PMID: 34399826    Free PMC article.
Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA.
Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal.
Hepat Oncol, 2021 Aug 20; 8(3). PMID: 34408847    Free PMC article.
Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
Masatoshi Kudo.
Liver Cancer, 2021 Aug 21; 10(4). PMID: 34414117    Free PMC article.
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
Shukui Qin, Zhenggang Ren, +12 authors, Ann Lii Cheng.
Liver Cancer, 2021 Aug 21; 10(4). PMID: 34414118    Free PMC article.
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.
Xiao-Dong Zhu, Cheng Huang, +12 authors, Hui-Chuan Sun.
Liver Cancer, 2021 Aug 21; 10(4). PMID: 34414120    Free PMC article.
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.
Fabian Finkelmeier, Bernhard Scheiner, +20 authors, Oliver Waidmann.
Liver Cancer, 2021 Aug 21; 10(4). PMID: 34414123    Free PMC article.
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.
Francesco Tovoli, Vincenzo Dadduzio, +22 authors, Fabio Piscaglia.
Liver Cancer, 2021 Aug 21; 10(4). PMID: 34414124    Free PMC article.
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.
Masahiro Morita, Naoshi Nishida, +11 authors, Masatoshi Kudo.
Liver Cancer, 2021 Aug 21; 10(4). PMID: 34414125    Free PMC article.
Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan.
Akinobu Taketomi.
JMA J, 2021 Aug 21; 4(3). PMID: 34414318    Free PMC article.
Review.
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma.
Xin Qing, Wenjing Xu, +3 authors, Yewei Zhang.
Biomark Res, 2021 Aug 23; 9(1). PMID: 34419152    Free PMC article.
Review.
The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma.
Zhongguang Chen, Lili Jiang, +5 authors, Junyan Tao.
Am J Pathol, 2021 May 18; 191(7). PMID: 34000282    Free PMC article.
Review.
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Riad Salem, Daneng Li, +4 authors, Riccardo Lencioni.
Cancer Med, 2021 Jul 01; 10(16). PMID: 34189869    Free PMC article.
TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27.
Chengpeng Yu, Dean Rao, +6 authors, Zeyang Ding.
Biomed Res Int, 2021 Aug 24; 2021. PMID: 34423034    Free PMC article.
Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion.
Taiji Tohyama, Kei Tamura, +3 authors, Yasutsugu Takada.
Langenbecks Arch Surg, 2021 Aug 25; 407(1). PMID: 34427752
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy.
Xiaobo Yang, Haifeng Xu, +13 authors, Haitao Zhao.
Hepatobiliary Surg Nutr, 2021 Aug 26; 10(4). PMID: 34430522    Free PMC article.
Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma.
Masatoshi Kudo.
Hepatobiliary Surg Nutr, 2021 Aug 26; 10(4). PMID: 34430534    Free PMC article.
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.
Romualdo Barroso-Sousa, Tanya E Keenan, +13 authors, Sara M Tolaney.
NPJ Breast Cancer, 2021 Aug 27; 7(1). PMID: 34433812    Free PMC article.
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.
Thibaud Koessler, Maria Alsina, +11 authors, Markus Moehler.
Br J Cancer, 2021 Aug 25; 125(7). PMID: 34426663    Free PMC article.
Review.
Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis.
Chieh-Min Liu, Bing-Shen Huang, +6 authors, Jen-Yu Cheng.
J Hepatocell Carcinoma, 2021 Aug 27; 8. PMID: 34434903    Free PMC article.
Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Song Chen, Zhiqiang Wu, +9 authors, Wenbo Guo.
J Cancer Res Clin Oncol, 2021 Aug 29;. PMID: 34453221
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Yuwa Ando, Tomokazu Kawaoka, +20 authors, Hiroshi Aikata.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439111    Free PMC article.
TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy.
Desh Deepak Singh, Dharmendra Kumar Yadav.
Biomedicines, 2021 Aug 28; 9(8). PMID: 34440080    Free PMC article.
Review.
The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
Liliana Montella, Federica Sarno, +9 authors, Gaetano Facchini.
Cells, 2021 Aug 28; 10(8). PMID: 34440678    Free PMC article.
Review.
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
Anna Michelotti, Marco de Scordilli, +6 authors, Fabio Puglisi.
Cells, 2021 Aug 28; 10(8). PMID: 34440803    Free PMC article.
Review.
The State of Immunotherapy in Hepatobiliary Cancers.
Farhan Z Ilyas, Joal D Beane, Timothy M Pawlik.
Cells, 2021 Aug 28; 10(8). PMID: 34440865    Free PMC article.
Review.
Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report.
Satoshi Komiyama, Kazushi Numata, +7 authors, Shin Maeda.
Diagnostics (Basel), 2021 Aug 28; 11(8). PMID: 34441328    Free PMC article.
Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.
Nicolas Jacquelot, Cyril Seillet, +3 authors, Pamela S Ohashi.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445750    Free PMC article.
Review.
Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease.
Alexa R Weingarden, Samuel J S Rubin, John Gubatan.
World J Gastrointest Oncol, 2021 Aug 31; 13(8). PMID: 34457186    Free PMC article.
Review.
Recent update on comprehensive therapy for advanced hepatocellular carcinoma.
Hui Wang, Wei Li.
World J Gastrointest Oncol, 2021 Aug 31; 13(8). PMID: 34457190    Free PMC article.
Review.
Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation.
Sandi A Kwee, Linda L Wong, +4 authors, Douglas P Landsittel.
J Vasc Interv Radiol, 2021 Jul 10; 32(9). PMID: 34242775    Free PMC article.
Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma.
Masafumi Akasu, Shu Shimada, +7 authors, Shinji Tanaka.
Sci Rep, 2021 Aug 26; 11(1). PMID: 34429454    Free PMC article.
Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade.
Naoki Okada, Ko Sugiyama, +5 authors, Akinobu Taketomi.
Cancer Immunol Immunother, 2021 Sep 06; 71(4). PMID: 34482409
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
Margherita Rimini, Changhoon Yoo, +15 authors, Andrea Casadei-Gardini.
Target Oncol, 2021 Sep 08; 16(5). PMID: 34491510
Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
Simon Wabitsch, Mayank Tandon, +8 authors, Tim F Greten.
Cell Mol Gastroenterol Hepatol, 2021 May 26; 12(3). PMID: 34033968    Free PMC article.
A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib.
Silvia Pietrobono, Davide Melisi.
Cell Mol Gastroenterol Hepatol, 2021 Jun 29; 12(3). PMID: 34181901    Free PMC article.
Immunotherapy in Hepatocellular Carcinoma.
Claudia A M Fulgenzi, Thomas Talbot, +4 authors, David J Pinato.
Curr Treat Options Oncol, 2021 Aug 24; 22(10). PMID: 34424422    Free PMC article.
Review.
YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.
Xinjun Lu, Baogang Peng, +12 authors, Jingxiao Wang.
Am J Pathol, 2021 Jun 16; 191(9). PMID: 34129844    Free PMC article.
Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Gang Liu, Wenxuan Zhou, +4 authors, Liansheng Gong.
Front Immunol, 2021 Sep 11; 12. PMID: 34504494    Free PMC article.
Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 Signaling.
Xiaobo Zheng, Peng Wang, +10 authors, Mingqing Xu.
Front Cell Dev Biol, 2021 Sep 11; 9. PMID: 34504839    Free PMC article.
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma.
Coskun O Demirtas, Antonio D'Alessio, +2 authors, David J Pinato.
JHEP Rep, 2021 Sep 11; 3(5). PMID: 34505035    Free PMC article.
Review.
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.
Taofei Zeng, Yuqing Cao, +3 authors, Feng Xu.
J Exp Clin Cancer Res, 2021 Sep 12; 40(1). PMID: 34507594    Free PMC article.
Review.
Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review.
Pierluigi Toniutto, Elisa Fumolo, Ezio Fornasiere, Davide Bitetto.
J Clin Med, 2021 Sep 11; 10(17). PMID: 34501381    Free PMC article.
Review.
Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy.
Panagiota Maravelia, Daniela Nascimento Silva, +4 authors, Anna Pasetto.
Cancers (Basel), 2021 Sep 11; 13(17). PMID: 34503144    Free PMC article.
Review.
IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Xiao Xiang, Ziyang Liu, +12 authors, Jiye Zhu.
Adv Sci (Weinh), 2021 Jul 13; 8(17). PMID: 34250753    Free PMC article.
Liver transplantation in malignant disease.
Sven Arke Lang, Jan Bednarsch, +8 authors, Ulf Peter Neumann.
World J Clin Oncol, 2021 Sep 14; 12(8). PMID: 34513597    Free PMC article.
Review.
Application of Immunotherapy in Hepatocellular Carcinoma.
Lele Miao, Zhengchao Zhang, Zhijian Ren, Yumin Li.
Front Oncol, 2021 Sep 14; 11. PMID: 34513678    Free PMC article.
Review.
Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances.
Jimmy Charneau, Toshihiro Suzuki, +2 authors, Tetsuya Nakatsura.
J Hepatocell Carcinoma, 2021 Sep 14; 8. PMID: 34513746    Free PMC article.
Review.
Deep Learning-Based Prediction of Future Extrahepatic Metastasis and Macrovascular Invasion in Hepatocellular Carcinoma.
Sirui Fu, Meiqing Pan, +14 authors, Jie Tian.
J Hepatocell Carcinoma, 2021 Sep 14; 8. PMID: 34513748    Free PMC article.
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Shu-Jin Li, Jia-Xian Chen, Zhi-Jun Sun.
Cancer Commun (Lond), 2021 Jun 18; 41(9). PMID: 34137513    Free PMC article.
Review.
Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte-rich hepatocellular carcinoma.
Ginji Omori, Takahiro Osuga, +11 authors, Junji Kato.
Clin Case Rep, 2021 Sep 16; 9(9). PMID: 34522383    Free PMC article.
An Overview of the Genomic Characterization of Hepatocellular Carcinoma.
Sun Young Yim, Ju-Seog Lee.
J Hepatocell Carcinoma, 2021 Sep 16; 8. PMID: 34522690    Free PMC article.
Review.
Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.
Abdul Rehman Khan, Xuyong Wei, Xiao Xu.
J Hepatocell Carcinoma, 2021 Sep 16; 8. PMID: 34522691    Free PMC article.
Review.
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma.
Ahmed Omar Kaseb, S Cheenu Kappadath, +15 authors, Armeen Mahvash.
J Hepatocell Carcinoma, 2021 Sep 17; 8. PMID: 34527608    Free PMC article.
Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis.
Jiaxi He, Hui Pan, Jianxing He, Shuben Li.
Ann Transl Med, 2021 Sep 18; 9(16). PMID: 34532422    Free PMC article.
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Shukui Qin, Feng Bi, +27 authors, Feng Chen.
J Clin Oncol, 2021 Jun 30; 39(27). PMID: 34185551    Free PMC article.
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Robin Kate Kelley, Bruno Sangro, +21 authors, Ghassan K Abou-Alfa.
J Clin Oncol, 2021 Jul 23; 39(27). PMID: 34292792    Free PMC article.
Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives.
Bing Feng, Xiao-Hong Ma, +3 authors, Xin-Ming Zhao.
World J Gastroenterol, 2021 Sep 21; 27(32). PMID: 34539136    Free PMC article.
Review.
Immune checkpoint inhibitor-related hepatotoxicity: A review.
Devika Remash, David S Prince, +3 authors, Ken Liu.
World J Gastroenterol, 2021 Sep 21; 27(32). PMID: 34539139    Free PMC article.
Review.
Comparison of intrahepatic progression patterns of hepatocellular carcinoma and colorectal liver metastases following CT-guided high dose-rate brachytherapy.
Han Xu, Robin Schmidt, +7 authors, Lynn Jeanette Savic.
Ther Adv Med Oncol, 2021 Sep 21; 13. PMID: 34539817    Free PMC article.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
Tim F Greten, Ghassan K Abou-Alfa, +18 authors, Ignacio Melero.
J Immunother Cancer, 2021 Sep 15; 9(9). PMID: 34518290    Free PMC article.
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy.
Yuqing He, Mengyao Lu, +3 authors, Yuan Chen.
Front Oncol, 2021 Sep 24; 11. PMID: 34552872    Free PMC article.
Review.
Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes.
Chonlakiet Khorprasert, Kanokphorn Thonglert, Petch Alisanant, Napapat Amornwichet.
PLoS One, 2021 Sep 24; 16(9). PMID: 34555075    Free PMC article.
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
Seoyoung Lee, Hyo Sup Shim, +4 authors, Min Hee Hong.
Cancer Immunol Immunother, 2021 Sep 28; 71(5). PMID: 34568975
Combination strategies to maximize the benefits of cancer immunotherapy.
Shaoming Zhu, Tian Zhang, +5 authors, Chong-Xian Pan.
J Hematol Oncol, 2021 Sep 29; 14(1). PMID: 34579759    Free PMC article.
Review.
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.
Dora Hammerl, John W M Martens, +12 authors, Reno Debets.
Nat Commun, 2021 Sep 29; 12(1). PMID: 34580291    Free PMC article.
Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Jianxin Chen, Junhui Wang, Fangwei Xie.
Medicine (Baltimore), 2021 Sep 25; 100(38). PMID: 34559096    Free PMC article.
Systematic Review.
Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes.
Robert Mahn, Farsaneh Sadeghlar, +13 authors, Maria A Gonzalez-Carmona.
Medicine (Baltimore), 2021 Sep 25; 100(38). PMID: 34559100    Free PMC article.
Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction.
Surabhi Pathak, Mohamad Bassam Sonbol.
J Hepatocell Carcinoma, 2021 Sep 30; 8. PMID: 34584898    Free PMC article.
Review.
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis.
Kento Inada, Shun Kaneko, +16 authors, Namiki Izumi.
JGH Open, 2021 Sep 30; 5(9). PMID: 34584979    Free PMC article.
Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden.
Joseph W Franses, Irun Bhan, +3 authors, Kenneth Tanabe.
JCO Precis Oncol, 2021 Sep 30; 5. PMID: 34585041    Free PMC article.
Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers.
Laura Gramantieri, Catia Giovannini, +2 authors, Francesca Fornari.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572776    Free PMC article.
Review.
Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis.
Michael Saerens, Emiel A De Jaeghere, +3 authors, Eline Naert.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572830    Free PMC article.
Review.
Reproducibility of CT-Based Hepatocellular Carcinoma Radiomic Features across Different Contrast Imaging Phases: A Proof of Concept on SORAMIC Trial Data.
Abdalla Ibrahim, Yousif Widaatalla, +11 authors, Philippe Lambin.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572870    Free PMC article.
How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma.
Giulia Martini, Davide Ciardiello, +12 authors, Erika Martinelli.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572944    Free PMC article.
Review.
Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective.
Vassilis G Giannakoulis, Peter Dubovan, +2 authors, John Koskinas.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572959    Free PMC article.
Review.
Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy.
Ji-Won Han, Seung-Kew Yoon.
Pharmaceutics, 2021 Sep 29; 13(9). PMID: 34575463    Free PMC article.
Review.
Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies.
Timothy C Huber, Teodora Bochnakova, +2 authors, Khashayar Farsad.
J Hepatocell Carcinoma, 2021 Oct 01; 8. PMID: 34589446    Free PMC article.
Review.
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma.
Betul Gok Yavuz, Elshad Hasanov, +5 authors, Ahmed O Kaseb.
J Hepatocell Carcinoma, 2021 Oct 02; 8. PMID: 34595140    Free PMC article.
Review.
Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
Wei Yu, Qiaomeng Tao, +2 authors, Long Feng.
J Oncol, 2021 Oct 05; 2021. PMID: 34603452    Free PMC article.
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study.
Hirva Mamdani, Bryan Schneider, +9 authors, Shadia I Jalal.
Front Oncol, 2021 Oct 05; 11. PMID: 34604072    Free PMC article.
Preparation of Near-Infrared/Photoacoustic Dual-Mode Imaging and Photothermal/Chemo Synergistic Theranostic Nanoparticles and Their Imaging and Treating of Hepatic Carcinoma.
Yun Zhou, Bixia Lin, +4 authors, Rajiv Kumar Jha.
Front Oncol, 2021 Oct 05; 11. PMID: 34604095    Free PMC article.
Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review.
Fausto Petrelli, Francesca Consoli, +5 authors, Salvatore Grisanti.
Front Immunol, 2021 Oct 08; 12. PMID: 34616395    Free PMC article.
Systematic Review.
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
Arndt Vogel, Philippe Merle, +14 authors, Masatoshi Kudo.
Ther Adv Med Oncol, 2021 Oct 08; 13. PMID: 34616489    Free PMC article.
Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy.
Ângelo Z Mattos, Jose D Debes, +2 authors, Angelo A Mattos.
World J Gastrointest Oncol, 2021 Oct 08; 13(9). PMID: 34616518    Free PMC article.
Review.
Progress of MRI Radiomics in Hepatocellular Carcinoma.
Xue-Qin Gong, Yun-Yun Tao, +11 authors, Xiao-Ming Zhang.
Front Oncol, 2021 Oct 08; 11. PMID: 34616673    Free PMC article.
Review.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Elaine Chang, Lorraine Pelosof, +15 authors, Marc R Theoret.
Oncologist, 2021 Jul 02; 26(10). PMID: 34196068    Free PMC article.
Review.
Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
F J Sherida H Woei-A-Jin, Nir I Weijl, +6 authors, Susanne Osanto.
Oncologist, 2021 Jul 13; 26(10). PMID: 34251745    Free PMC article.
Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.
Lei Dai, Xingchen Cai, +4 authors, Caide Lu.
Sci Rep, 2021 Oct 07; 11(1). PMID: 34611195    Free PMC article.
Radioembolization in the Setting of Systemic Therapies.
Tarub S Mabud, Ryan Hickey.
Semin Intervent Radiol, 2021 Oct 12; 38(4). PMID: 34629716    Free PMC article.
Review.
Epigenetic mechanisms of liver tumor resistance to immunotherapy.
Julie Sanceau, Angélique Gougelet.
World J Hepatol, 2021 Oct 12; 13(9). PMID: 34630870    Free PMC article.
Review.
Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice.
Ankit Jain, Shivakumar Chitturi, Geoffrey Peters, Desmond Yip.
World J Hepatol, 2021 Oct 12; 13(9). PMID: 34630880    Free PMC article.
Review.
The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.
Fangzhou Luo, Mengxia Li, Jun Ding, Shusen Zheng.
Front Oncol, 2021 Oct 12; 11. PMID: 34631513    Free PMC article.
Review.
Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.
Haichuan Wang, Xin Chen, Diego F Calvisi.
Expert Opin Ther Targets, 2021 Sep 04; 25(8). PMID: 34477018    Free PMC article.
Review.
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
David J Pinato, Sam M Murray, +18 authors, Vincenzo Mazzaferro.
J Immunother Cancer, 2021 Oct 02; 9(9). PMID: 34593621    Free PMC article.
The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma.
Noe Rico Montanari, Chimaobi M Anugwom, Andre Boonstra, Jose D Debes.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638361    Free PMC article.
Review.
Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation.
Filippo Pelizzaro, Martina Gambato, +5 authors, Francesco Paolo Russo.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638365    Free PMC article.
Review.
Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials.
Bang-Bin Chen, Zhong-Zhe Lin, +5 authors, Tiffany Ting-Fang Shih.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638446    Free PMC article.
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.
Soon Kyu Lee, Sung Won Lee, +3 authors, Seung Kew Yoon.
Int J Mol Sci, 2021 Oct 14; 22(19). PMID: 34638613    Free PMC article.
Review.
The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives.
Robert J Walsh, David S P Tan.
J Clin Med, 2021 Oct 14; 10(19). PMID: 34640541    Free PMC article.
Review.
Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
Yuchen Guo, Jun Wang, +15 authors, Cun Wang.
Genome Med, 2021 Oct 20; 13(1). PMID: 34663432    Free PMC article.
Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Song Chen, Bo Xu, +7 authors, Wenbo Guo.
BMC Cancer, 2021 Oct 22; 21(1). PMID: 34670506    Free PMC article.
Organoids for the Study of Liver Cancer.
Haichuan Wang, Diego F Calvisi, Xin Chen.
Semin Liver Dis, 2021 Mar 26; 41(1). PMID: 33764482    Free PMC article.
Review.
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Enriqueta Felip, Mauricio Burotto, +12 authors, Eleonora Restuccia.
Clin Pharmacol Drug Dev, 2021 Apr 01; 10(10). PMID: 33788415    Free PMC article.
Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Ziniu Ding, Zhaoru Dong, +8 authors, Tao Li.
Front Immunol, 2021 Oct 19; 12. PMID: 34659220    Free PMC article.
Systematic Review.
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
Francesca Negri, Camillo Porta.
Oncol Rev, 2021 Oct 21; 15(2). PMID: 34667489    Free PMC article.
Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes.
Jiahao Yu, Shuoyi Ma, +9 authors, Ying Han.
Front Cell Dev Biol, 2021 Oct 22; 9. PMID: 34671598    Free PMC article.
Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib.
Yanjun Shen, Huige Wang, Jianying Wei, Wendong Li.
Onco Targets Ther, 2021 Oct 23; 14. PMID: 34675546    Free PMC article.
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Zhuoyan Liu, Xuan Liu, +5 authors, Xiaotao Jiang.
Front Immunol, 2021 Oct 23; 12. PMID: 34675942    Free PMC article.
Review.
Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Jia-Yi Wu, Zhen-Yu Yin, +8 authors, Mao-Lin Yan.
J Hepatocell Carcinoma, 2021 Oct 23; 8. PMID: 34676181    Free PMC article.
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Yuji Eso, Haruhiko Takeda, +3 authors, Hiroshi Seno.
Curr Oncol, 2021 Oct 23; 28(5). PMID: 34677270    Free PMC article.
In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?
Ana-Maria Bucalau, Illario Tancredi, Gontran Verset.
Cancers (Basel), 2021 Oct 24; 13(20). PMID: 34680278    Free PMC article.
Review.
HCC and Molecular Targeting Therapies: Back to the Future.
Luca Rinaldi, Erica Vetrano, +4 authors, Ferdinando Carlo Sasso.
Biomedicines, 2021 Oct 24; 9(10). PMID: 34680462    Free PMC article.
Review.
The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances.
James R Janopaul-Naylor, Yang Shen, David C Qian, Zachary S Buchwald.
Int J Mol Sci, 2021 Oct 24; 22(20). PMID: 34681719    Free PMC article.
Review.
Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review.
Dae Sik Yang, Sunmin Park, +3 authors, Han Ah Lee.
Medicina (Kaunas), 2021 Oct 24; 57(10). PMID: 34684036    Free PMC article.
Systematic Review.
Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis.
Gun Ha Kim, Sang Lim Choi, +3 authors, Nayoung Kim.
Life (Basel), 2021 Oct 24; 11(10). PMID: 34685437    Free PMC article.
Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al.
Alessandro Rizzo.
Transl Oncol, 2021 Oct 18; 14(12). PMID: 34656968    Free PMC article.
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Shigeki Yano, Tomokazu Kawaoka, +24 authors, Hiroshi Aikata.
Medicine (Baltimore), 2021 Oct 23; 100(42). PMID: 34678902    Free PMC article.
Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
Mengzhou Guo, Feng Qi, +5 authors, Jinglin Xia.
Front Immunol, 2021 Oct 26; 12. PMID: 34691076    Free PMC article.
The Immunology of Hepatocellular Carcinoma.
Gbemisola Lawal, Yao Xiao, +4 authors, Timothy M Pawlik.
Vaccines (Basel), 2021 Oct 27; 9(10). PMID: 34696292    Free PMC article.
Review.
Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment.
Yu-Chao Wang, Jin-Chiao Lee, +6 authors, Wei-Chen Lee.
World J Surg Oncol, 2021 Oct 28; 19(1). PMID: 34702312    Free PMC article.
Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials.
Lisha Mou, Xiaohe Tian, +13 authors, Zuhui Pu.
Front Oncol, 2021 Oct 29; 11. PMID: 34707994    Free PMC article.
Review.
Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis.
Linhan Jiang, Xiaoxia Tan, Jun Li, Yaling Li.
Front Oncol, 2021 Oct 30; 11. PMID: 34712609    Free PMC article.
Systematic Review.
The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Alexander D Murphy, Robert D Morgan, Andrew R Clamp, Gordon C Jayson.
Br J Cancer, 2021 Oct 31; 126(6). PMID: 34716396    Free PMC article.
Review.
Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Jianjun Xu, Qichang Zheng, +11 authors, Yang Gao.
J Nanobiotechnology, 2021 Nov 01; 19(1). PMID: 34717654    Free PMC article.
"γδT Cell-IL17A-Neutrophil" Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy.
Zhigang Zhang, Chenghui Yang, +5 authors, Jian Huang.
Front Immunol, 2021 Nov 02; 12. PMID: 34721375    Free PMC article.
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721502    Free PMC article.
Role of Liver Resection for Hepatocellular Carcinoma with Vascular Invasion: Emerging Evidence from Western Countries.
Norihiro Kokudo, Takashi Kokudo, Kiyoshi Hasegawa.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721503    Free PMC article.
Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis.
Rajalakshmi Govalan, Marie Lauzon, +15 authors, Ju Dong Yang.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721504    Free PMC article.
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
Masatoshi Kudo, Richard S Finn, +15 authors, Andrew X Zhu.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721507    Free PMC article.
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Keisuke Koroki, Naoya Kanogawa, +37 authors, Naoya Kato.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721509    Free PMC article.
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
Colby S Shemesh, Phyllis Chan, +5 authors, Benjamin Wu.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721510    Free PMC article.
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
Zhenggang Ren, Shukui Qin, +13 authors, Jianjun Zou.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721511    Free PMC article.
Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions.
Xiao-Wan Bo, Li-Ping Sun, Song-Yuan Yu, Hui-Xiong Xu.
World J Gastrointest Oncol, 2021 Nov 02; 13(10). PMID: 34721773    Free PMC article.
Review.
Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review.
Haris Muhammad, Aniqa Tehreem, +7 authors, Ahmet Gurakar.
J Clin Transl Hepatol, 2021 Nov 02; 9(5). PMID: 34722189    Free PMC article.
Review.
Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models.
Shanshan Deng, Antonio Solinas, Diego F Calvisi.
Front Oncol, 2021 Nov 02; 11. PMID: 34722310    Free PMC article.
Review.
Breast cancer immune microenvironment: from pre-clinical models to clinical therapies.
Brooke E Wilson, Chiara Gorrini, David W Cescon.
Breast Cancer Res Treat, 2021 Nov 04; 191(2). PMID: 34731350
Review.
The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States.
Yi-Te Lee, Jasmine J Wang, +9 authors, Ju Dong Yang.
J Natl Cancer Inst, 2021 May 20; 113(11). PMID: 34010422    Free PMC article.
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Kanwal Raghav, Suyu Liu, +31 authors, Daniel M Halperin.
Cancer Discov, 2021 Jul 16; 11(11). PMID: 34261675    Free PMC article.
Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
Xin Li, Jiahua Xu, +6 authors, Jianxin Qian.
Front Immunol, 2021 Nov 05; 12. PMID: 34733279    Free PMC article.
Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection.
Jian-Hong Peng, Yi Tai, +5 authors, Zhen-Hai Lu.
Gastroenterol Rep (Oxf), 2021 Nov 05; 9(5). PMID: 34733530    Free PMC article.
Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study.
Guosheng Yuan, Rong Li, +7 authors, Jinzhang Chen.
Ann Transl Med, 2021 Nov 05; 9(18). PMID: 34733964    Free PMC article.
Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective.
Gun Ha Kim, Jin Hyoung Kim, +3 authors, Heung-Kyu Ko.
Korean J Radiol, 2021 Aug 26; 22(11). PMID: 34431250    Free PMC article.
Review.
Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis.
Qinqin Liu, Nan You, +6 authors, Lu Zheng.
Front Oncol, 2021 Nov 06; 11. PMID: 34737945    Free PMC article.
Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients.
Wenwen Zhang, Bingyang Hu, +14 authors, Shichun Lu.
Front Oncol, 2021 Nov 06; 11. PMID: 34737958    Free PMC article.
Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels.
Jiamin Cheng, Yinyin Li, +10 authors, Zhen Zeng.
J Hepatocell Carcinoma, 2021 Nov 06; 8. PMID: 34737983    Free PMC article.
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges.
Hao-Tian Liu, Meng-Jie Jiang, +5 authors, Jian-Hong Zhong.
Front Oncol, 2021 Nov 09; 11. PMID: 34745958    Free PMC article.
Review.
[Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib].
Liling Huang, Yan Qin, +2 authors, Yuankai Shi.
Zhongguo Fei Ai Za Zhi, 2021 Oct 11; 24(10). PMID: 34628779    Free PMC article.
Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma.
Lin-Lin Zheng, Chang-Cheng Tao, +4 authors, Wei-Qi Rong.
World J Gastrointest Surg, 2021 Nov 11; 13(10). PMID: 34754383    Free PMC article.
Review.
The upward trend in the immunotherapy utilization for hepatobiliary cancers.
Xiao-Bu Lan, George Papatheodoridis, Yu-Xian Teng, Jian-Hong Zhong.
Hepatobiliary Surg Nutr, 2021 Nov 12; 10(5). PMID: 34760976    Free PMC article.
Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma.
Bo-Han Zhang, Yun-Shi Cai, Li Jiang, Jia-Yin Yang.
Hepatobiliary Surg Nutr, 2021 Nov 12; 10(5). PMID: 34760990    Free PMC article.
Immunotherapies for hepatocellular carcinoma.
Josep M Llovet, Florian Castet, +6 authors, Richard S Finn.
Nat Rev Clin Oncol, 2021 Nov 13; 19(3). PMID: 34764464
Review.
Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.
Sarah Ronnebaum, Abdalla Aly, +2 authors, Juan-David Rueda.
Hepat Oncol, 2021 Nov 13; 9(1). PMID: 34765109    Free PMC article.
Review.
The past, present and future of conversion therapy for liver cancer.
Tianqiang Song, Mengran Lang, +2 authors, Wei Lu.
Am J Cancer Res, 2021 Nov 13; 11(10). PMID: 34765289    Free PMC article.
Review.
Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
Yalda Dehghan, Gabriel T Schnickel, +8 authors, Yuko Kono.
Clin J Gastroenterol, 2021 Oct 14; 14(6). PMID: 34643885    Free PMC article.
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
Ravi B Parikh, Eun Jeong Min, +6 authors, Ronac Mamtani.
JAMA Oncol, 2021 Nov 05; 7(12). PMID: 34734979    Free PMC article.
Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis.
Yuki Zaizen, Masahito Nakano, +17 authors, Takuji Torimura.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771452    Free PMC article.
Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma.
Pei-Yi Chu, Shih-Hsuan Chan.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771459    Free PMC article.
Review.
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Kylie E Zane, Mina S Makary.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771593    Free PMC article.
Review.
Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy.
Masatoshi Kudo.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771637    Free PMC article.
Review.
Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma.
James M Henderson, Michelle S W Xiang, +10 authors, Mark D Gorrell.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771657    Free PMC article.
Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities.
Sharanya Maanasi Kalasekar, Chad H VanSant-Webb, Kimberley J Evason.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771685    Free PMC article.
Review.
Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma.
Tamás Sükei, Elena Palma, Luca Urbani.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771746    Free PMC article.
Review.
Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC).
Yihe Yan, Leting Zheng, Qiang Du, David A Geller.
Oncotarget, 2021 Nov 18; 12(23). PMID: 34786183    Free PMC article.
Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer.
Qitong Zheng, Chen Wu, +6 authors, Feng Cheng.
Ann Transl Med, 2021 Nov 19; 9(20). PMID: 34790774    Free PMC article.
Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Takashi Egawa, Keita Masuzawa, +4 authors, Yusuke Suzuki.
Intern Med, 2021 Apr 13; 60(20). PMID: 33840693    Free PMC article.
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit.
Alexa Childs, Nekisa Zakeri, +16 authors, Tim Meyer.
Br J Cancer, 2021 Sep 17; 125(10). PMID: 34526664    Free PMC article.
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Won Jin Ho, Qingfeng Zhu, +28 authors, Mark Yarchoan.
Nat Cancer, 2021 Nov 20; 2(9). PMID: 34796337    Free PMC article.
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Lichun Ma, Limin Wang, +15 authors, Xin Wei Wang.
J Hepatol, 2021 Jul 04; 75(6). PMID: 34216724    Free PMC article.
Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Shankun Zhao, Weizhou Wu, +6 authors, Kunpeng Wang.
Front Immunol, 2021 Nov 23; 12. PMID: 34804015    Free PMC article.
Review.
Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy.
Jian Xue, Hongbo Ni, +2 authors, Meng Niu.
J Interv Med, 2021 Nov 23; 4(3). PMID: 34805958    Free PMC article.
Review.
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Patrick A Ott, Matthew Nazzaro, +12 authors, F Stephen Hodi.
J Immunother Cancer, 2021 Nov 14; 9(11). PMID: 34772758    Free PMC article.
Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment.
Shohei Mukai, Hiroaki Kanzaki, +30 authors, Naoya Kato.
JGH Open, 2021 Nov 25; 5(11). PMID: 34816012    Free PMC article.
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma.
Tetsu Tomonari, Yasushi Sato, +9 authors, Tetsuji Takayama.
JGH Open, 2021 Nov 25; 5(11). PMID: 34816013    Free PMC article.
The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West.
Yi-Hao Yen, Wei-Feng Li, +5 authors, Chao-Hung Hung.
Langenbecks Arch Surg, 2021 Nov 27; 407(1). PMID: 34825277
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
Eun Jin Sun, Miriam Wankell, +2 authors, Lionel Hebbard.
Biomedicines, 2021 Nov 28; 9(11). PMID: 34829868    Free PMC article.
Review.
Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC.
Pierpaolo Biondetti, Lorenzo Saggiante, +6 authors, Gianpaolo Carrafiello.
Cancers (Basel), 2021 Nov 28; 13(22). PMID: 34830949    Free PMC article.
Review.
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors.
Nicola Personeni, Tiziana Pressiani, +13 authors, Lorenza Rimassa.
Cancers (Basel), 2021 Nov 28; 13(22). PMID: 34830823    Free PMC article.
Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization.
Tuyana Boldanova, Geoffrey Fucile, +8 authors, Markus H Heim.
Cell Rep Med, 2021 Nov 30; 2(11). PMID: 34841291    Free PMC article.
A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Yukinobu Watanabe, Masahiro Ogawa, +7 authors, Mitsuhiko Moriyama.
J Investig Med High Impact Case Rep, 2021 Dec 01; 9. PMID: 34845921    Free PMC article.
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
Faiza Ahmed, Jennifer Onwumeh-Okwundu, +9 authors, Endrit Shahini.
World J Gastrointest Oncol, 2021 Dec 03; 13(11). PMID: 34853653    Free PMC article.
Treatment for Hepatocellular Carcinoma in South Asia.
Subrat K Acharya.
J Clin Exp Hepatol, 2021 Dec 07; 11(6). PMID: 34866841    Free PMC article.
Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study.
Jinliang Zhang, Xihao Zhang, +4 authors, Ti Zhang.
Front Oncol, 2021 Dec 07; 11. PMID: 34868921    Free PMC article.
Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview.
Hui-Chuan Sun, Xiao-Dong Zhu.
Front Oncol, 2021 Dec 07; 11. PMID: 34869008    Free PMC article.
Review.
Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Alexandre A Jácome, Ana Carolina G Castro, +9 authors, Bernardo Garicochea.
JAMA Netw Open, 2021 Dec 07; 4(12). PMID: 34870682    Free PMC article.
Systematic Review.
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.
Katharina Pomej, Lorenz Balcar, +7 authors, Matthias Pinter.
J Hepatocell Carcinoma, 2021 Dec 09; 8. PMID: 34877268    Free PMC article.
Estrogen Receptor 1 Inhibition of Wnt/β-Catenin Signaling Contributes to Sex Differences in Hepatocarcinogenesis.
Mamatha Bhat, Elisa Pasini, +7 authors, Igor Jurisica.
Front Oncol, 2021 Dec 10; 11. PMID: 34881186    Free PMC article.
The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.
Frazer Warricker, Salim I Khakoo, Matthew D Blunt.
J Transl Genet Genom, 2021 Dec 11; 5. PMID: 34888493    Free PMC article.
Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma.
Ching-Tso Chen, Tsung-Hao Liu, +3 authors, Zhong-Zhe Lin.
Int J Mol Sci, 2021 Dec 11; 22(23). PMID: 34884684    Free PMC article.
Review.
Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.
María Lola Espejo-Cruz, Sandra González-Rubio, +7 authors, Gustavo Ferrín.
Int J Mol Sci, 2021 Dec 11; 22(23). PMID: 34884878    Free PMC article.
Review.
Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma.
Shusil K Pandit, Giada Sandrini, +7 authors, Carlo V Catapano.
Cancers (Basel), 2021 Dec 11; 13(23). PMID: 34885140    Free PMC article.
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Rui Xing, Jinping Gao, Qi Cui, Qian Wang.
Front Immunol, 2021 Dec 14; 12. PMID: 34899747    Free PMC article.
Review.
Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
Lingli Fu, Ping Chen, +4 authors, Zhenming Fu.
Anticancer Drugs, 2021 Aug 03; 33(1). PMID: 34338239    Free PMC article.
Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC.
Adnan Zaidi, Shahid Ahmed, +18 authors, Mike Moser.
Curr Oncol, 2021 Dec 14; 28(6). PMID: 34898545    Free PMC article.
CRISPR/Cas9 in Gastrointestinal Malignancies.
André Jefremow, Markus F Neurath, Maximilian J Waldner.
Front Cell Dev Biol, 2021 Dec 17; 9. PMID: 34912798    Free PMC article.
Review.
Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Yu-Jie Xu, Zhi-Cheng Lai, +10 authors, Qi-Jiong Li.
Technol Cancer Res Treat, 2021 Dec 14; 20. PMID: 34898313    Free PMC article.
Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.
Layana Biglow, Sara Ashraf, Mohamed Alsharedi.
Stem Cell Investig, 2021 Dec 18; 8. PMID: 34917675    Free PMC article.
Review.
Multi-task deep learning network to predict future macrovascular invasion in hepatocellular carcinoma.
Sirui Fu, Haoran Lai, +11 authors, Ligong Lu.
EClinicalMedicine, 2021 Dec 18; 42. PMID: 34917908    Free PMC article.
A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis.
Fan Yao, Yalan Deng, +22 authors, Li Ma.
Nat Commun, 2021 Dec 19; 12(1). PMID: 34921145    Free PMC article.
Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Shohei Komatsu, Yoshimi Fujishima, +5 authors, Takumi Fukumoto.
BMC Gastroenterol, 2021 Dec 17; 21(1). PMID: 34911458    Free PMC article.
Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
Min Deng, Jia-Bao Lin, +5 authors, Rong-Ping Guo.
BMC Cancer, 2021 Dec 21; 21(1). PMID: 34923955    Free PMC article.
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
Amit M Oza, François Dubois, +8 authors, Nicoletta Colombo.
Oncologist, 2021 Sep 10; 26(12). PMID: 34498344    Free PMC article.
VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment.
Yuqing Zhang, Huocong Huang, +4 authors, Rolf A Brekken.
JCI Insight, 2021 Oct 22; 6(23). PMID: 34673569    Free PMC article.
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Jinzhu Mao, Dongxu Wang, +19 authors, Haitao Zhao.
J Immunother Cancer, 2021 Dec 08; 9(12). PMID: 34873013    Free PMC article.
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.
Masatoshi Kudo.
Liver Cancer, 2021 Dec 25; 10(6). PMID: 34950177    Free PMC article.
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
María Gutiérrez-Larrañaga, Elena González-López, +6 authors, Javier Crespo.
Liver Cancer, 2021 Dec 25; 10(6). PMID: 34950178    Free PMC article.
Review.
Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.
Tomoko Aoki, Naoshi Nishida, +10 authors, Masatoshi Kudo.
Liver Cancer, 2021 Dec 25; 10(6). PMID: 34950184    Free PMC article.
Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Chi-Leung Chiang, Keith Wan-Hang Chiu, +2 authors, Albert Chi-Yan Chan.
Front Oncol, 2021 Dec 25; 11. PMID: 34950594    Free PMC article.
Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.
Yusuke Sugama, Koji Miyanishi, +10 authors, Junji Kato.
JGH Open, 2021 Dec 25; 5(12). PMID: 34950776    Free PMC article.
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.
Christian U Blank, Deborah J Wong, +7 authors, Mario Sznol.
Curr Oncol, 2021 Dec 24; 28(6). PMID: 34940094    Free PMC article.
Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
Noreen Nog-Qin Chui, Jacinth Wing-Sum Cheu, +6 authors, Carmen Chak-Lui Wong.
Hepatol Commun, 2021 Sep 25; 6(1). PMID: 34558800    Free PMC article.
Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.
Qimeng Gao, Imran J Anwar, Nader Abraham, Andrew S Barbas.
Cancers (Basel), 2021 Dec 25; 13(24). PMID: 34944927    Free PMC article.
Review.
Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.
Marie Decraecker, Caroline Toulouse, Jean-Frédéric Blanc.
Cancers (Basel), 2021 Dec 25; 13(24). PMID: 34944930    Free PMC article.
Review.
Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation.
Marco Biolato, Tiziano Galasso, +2 authors, Antonio Grieco.
Cancers (Basel), 2021 Dec 25; 13(24). PMID: 34944957    Free PMC article.
Review.
Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors.
Alejandro Olivares-Hernández, Luis Figuero-Pérez, +4 authors, Emilio Fonseca-Sánchez.
Life (Basel), 2021 Dec 25; 11(12). PMID: 34947931    Free PMC article.
Review.
The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.
Muhammet Ozer, Andrew George, +2 authors, Ilyas Sahin.
Front Oncol, 2021 Dec 28; 11. PMID: 34956912    Free PMC article.
Review.
An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma.
Long Liu, Zaoqu Liu, +7 authors, Shuijun Zhang.
Front Mol Biosci, 2022 Jan 01; 8. PMID: 34970594    Free PMC article.
Immunotherapy in Gastrointestinal Malignancies.
Rishi Surana, Shubham Pant.
Adv Exp Med Biol, 2022 Jan 02; 1342. PMID: 34972968
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1low and immune desert‑like mouse tumors.
Nobuyuki Ishikura, Masamichi Sugimoto, +2 authors, Osamu Kondoh.
Oncol Rep, 2021 Dec 28; 47(2). PMID: 34958105    Free PMC article.
Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.
Wenhui Liu, Fang Ma, +5 authors, Zhiying Luo.
Front Immunol, 2022 Jan 04; 12. PMID: 34975845    Free PMC article.
Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.
Kunpeng Wang, Cong Wang, +4 authors, Chong Jin.
Front Immunol, 2022 Jan 04; 12. PMID: 34975896    Free PMC article.
Review.
Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.
Tin-Yun Tang, Katherine Daunov, Richard T Lee.
Front Oncol, 2022 Jan 04; 11. PMID: 34976819    Free PMC article.
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, +4 authors, Giovanni Brandi.
Front Oncol, 2022 Jan 04; 11. PMID: 34976841    Free PMC article.
Review.
Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy.
Yan Li, Chen Yang, +13 authors, Huimin Chen.
Mol Cancer, 2022 Jan 05; 21(1). PMID: 34980132    Free PMC article.
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
Amaia Martinez-Usatorre, Ece Kadioglu, +10 authors, Michele De Palma.
Sci Transl Med, 2021 Aug 13; 13(606). PMID: 34380768    Free PMC article.
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
M Rimini, M Kudo, +59 authors, A Casadei-Gardini.
ESMO Open, 2021 Dec 01; 6(6). PMID: 34847382    Free PMC article.
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Osman Öcal, Regina Schinner, +15 authors, SORAMIC study group.
Cancer Imaging, 2022 Jan 06; 22(1). PMID: 34983668    Free PMC article.
Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases.
Tong Wu, Linzhi Zhang, +4 authors, Yinying Lu.
Onco Targets Ther, 2022 Jan 06; 14. PMID: 34984004    Free PMC article.
The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Fei Cao, Yi Yang, +6 authors, Jiaping Zheng.
Front Oncol, 2022 Jan 07; 11. PMID: 34988019    Free PMC article.
Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.
Valerie J W Tong, Vishal G Shelat, Yew Kuo Chao.
J Clin Transl Res, 2022 Jan 07; 7(6). PMID: 34988334    Free PMC article.
Review.
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shigeo Shimose, Atsushi Hiraoka, +21 authors, Takuji Torimura.
Cancer Med, 2021 Oct 26; 10(23). PMID: 34693661    Free PMC article.
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.
Valentina Burgio, Massimo Iavarone, +34 authors, Andrea Casadei-Gardini.
Cancer Manag Res, 2022 Jan 08; 13. PMID: 34992463    Free PMC article.
Recent advances in systemic therapy for hepatocellular carcinoma.
Huajun Zhang, Wuyang Zhang, Longying Jiang, Yongheng Chen.
Biomark Res, 2022 Jan 11; 10(1). PMID: 35000616    Free PMC article.
Review.
Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy.
Khalil Choucair, Syed Kamran, Anwaar Saeed.
Onco Targets Ther, 2022 Jan 11; 14. PMID: 35002257    Free PMC article.
Review.
Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer.
Yan-Yan Hao, Yi-Peng Qiao, Jian-De Cheng.
Int J Gen Med, 2022 Jan 11; 14. PMID: 35002304    Free PMC article.
First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Wenfeng Liu, Bing Quan, +5 authors, Xin Yin.
Front Oncol, 2022 Jan 11; 11. PMID: 35004289    Free PMC article.
Systematic Review.
Systemic treatment of hepatocellular carcinoma: the times they are a-changin'.
Claudia Campani, Jean-Charles Nault.
Hepatobiliary Surg Nutr, 2022 Jan 11; 10(6). PMID: 35004965    Free PMC article.
Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.
Yi Sun, Wei Chen, +20 authors, Yuwen Zhu.
Sci Transl Med, 2021 Jul 30; 13(604). PMID: 34321321    Free PMC article.
Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
Wendy S Chen, Yan Liang, +5 authors, Gen-Sheng Feng.
Cell Rep, 2021 Nov 11; 37(6). PMID: 34758313    Free PMC article.
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Benjamin Wu, Nitzan Sternheim, +11 authors, Valerie Quarmby.
Clin Transl Sci, 2021 Aug 26; 15(1). PMID: 34432389    Free PMC article.
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
Solange Peters, Peter R Galle, +8 authors, Martin Reck.
Clin Transl Sci, 2021 Sep 29; 15(1). PMID: 34582105    Free PMC article.
Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo.
J Histochem Cytochem, 2021 Nov 10; 70(1). PMID: 34751050    Free PMC article.
Review.
Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Miao Xue, Yanqin Wu, +3 authors, Jiaping Li.
Am J Cancer Res, 2022 Jan 13; 11(12). PMID: 35018245    Free PMC article.
Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.
Wei-Fan Hsu, Hung-Wei Wang, +14 authors, Cheng-Yuan Peng.
Am J Cancer Res, 2022 Jan 13; 11(12). PMID: 35018250    Free PMC article.
Neutrophils as potential therapeutic targets in hepatocellular carcinoma.
Daniel Geh, Jack Leslie, +3 authors, Derek A Mann.
Nat Rev Gastroenterol Hepatol, 2022 Jan 14; 19(4). PMID: 35022608
Review.
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Ayumi Hashimoto, Debashis Sarker, +28 authors, Dmitry I Gabrilovich.
Clin Cancer Res, 2021 Aug 20; 27(21). PMID: 34407972    Free PMC article.
Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities.
Ester García-Pras, Anabel Fernández-Iglesias, Jordi Gracia-Sancho, Sofía Pérez-Del-Pulgar.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008212    Free PMC article.
Review.
Systematic Investigation of Biocompatible Cationic Polymeric Nucleic Acid Carriers for Immunotherapy of Hepatocellular Carcinoma.
Mingsheng Chen, Hao Wang, +2 authors, Liang Chen.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008249    Free PMC article.
Review.
Novel Molecular Targets for Hepatocellular Carcinoma.
Beatrice Cavalluzzo, Angela Mauriello, +7 authors, Luigi Buonaguro.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008303    Free PMC article.
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.
Ambreen Muhammed, Claudia Angela Maria Fulgenzi, +36 authors, David J Pinato.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008350    Free PMC article.
Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy.
Konstantinos Arvanitakis, Triantafyllia Koletsa, Ioannis Mitroulis, Georgios Germanidis.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008390    Free PMC article.
Review.
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
Zijian Yang, Goki Suda, +18 authors, Naoya Sakamoto.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008398    Free PMC article.
Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
Francesco Paolo Russo, Alberto Zanetto, +4 authors, Fabio Farinati.
Int J Mol Sci, 2022 Jan 12; 23(1). PMID: 35008926    Free PMC article.
Review.
Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma.
Barbara Chiavarina, Roberto Ronca, +18 authors, Andrei Turtoi.
Oncogene, 2022 Jan 16; 41(10). PMID: 35031773
Hepatocellular Carcinoma with Extensive Macrovascular Invasion.
Joshua A Rushakoff, Lili Shek.
J Gen Intern Med, 2022 Jan 16; 37(7). PMID: 35031948
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Christophe Maritaz, Sophie Broutin, +2 authors, Angelo Paci.
J Hematol Oncol, 2022 Jan 17; 15(1). PMID: 35033167    Free PMC article.
Review.
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
San-Chi Chen, Yi-Hsiang Huang, +4 authors, Yee Chao.
BMC Cancer, 2022 Jan 13; 22(1). PMID: 35016637    Free PMC article.
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.
Golnaz Morad, Beth A Helmink, Padmanee Sharma, Jennifer A Wargo.
Cell, 2021 Oct 09; 184(21). PMID: 34624224    Free PMC article.
Review.
The management of post-transplantation recurrence of hepatocellular carcinoma.
Luckshi Rajendran, Tommy Ivanics, +2 authors, Gonzalo Sapisochin.
Clin Mol Hepatol, 2021 Oct 06; 28(1). PMID: 34610652    Free PMC article.
Review.
Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.
Adam Mor, Marianne Strazza.
Front Cell Dev Biol, 2022 Jan 21; 9. PMID: 35047501    Free PMC article.
Review.
Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database.
Riad Salem, Ahmed Gabr.
J Nucl Med, 2021 Dec 18; 63(1). PMID: 34916247    Free PMC article.
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Ming Yi, Xiaoli Zheng, +3 authors, Kongming Wu.
Mol Cancer, 2022 Jan 23; 21(1). PMID: 35062949    Free PMC article.
Review.
Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?
Zeno Sparchez, Pompilia Radu, +6 authors, Jean-François Dufour.
World J Gastrointest Oncol, 2022 Jan 25; 13(12). PMID: 35070032    Free PMC article.
Review.
Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.
Saleh A Alqahtani, Massimo G Colombo.
World J Gastrointest Oncol, 2022 Jan 25; 13(12). PMID: 35070040    Free PMC article.
Review.
Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
Takuya Sho, Kenichi Morikawa, +10 authors, Naoya Sakamoto.
World J Gastrointest Oncol, 2022 Jan 25; 13(12). PMID: 35070043    Free PMC article.
Review.
Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma?
Feng Zhu, Bi-Rong Wang, +4 authors, Min Li.
World J Gastrointest Surg, 2022 Jan 25; 13(12). PMID: 35070061    Free PMC article.
Neoadjuvant treatment strategies for hepatocellular carcinoma.
Lei Xu, Lin Chen, Wei Zhang.
World J Gastrointest Surg, 2022 Jan 25; 13(12). PMID: 35070063    Free PMC article.
Review.
Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI.
Akifumi Kuwano, Kosuke Tanaka, +4 authors, Kenta Motomura.
Mol Clin Oncol, 2022 Jan 25; 16(2). PMID: 35070302    Free PMC article.
Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma.
Aydin Eresen, Zhuoli Zhang, Vahid Yaghmai.
Ann Transl Med, 2022 Jan 25; 9(23). PMID: 35071439    Free PMC article.
Review.
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
Taito Fukushima, Manabu Morimoto, +14 authors, Shin Maeda.
JGH Open, 2022 Jan 25; 6(1). PMID: 35071785    Free PMC article.
Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.
Yi Zhou, Junyan Tao, Diego F Calvisi, Xin Chen.
Semin Liver Dis, 2021 Jul 27; 42(1). PMID: 34311471    Free PMC article.
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.
Ching-Hung Hsieh, Cheng-Zhe Jian, +4 authors, Da-Liang Ou.
Cancers (Basel), 2022 Jan 22; 14(2). PMID: 35053457    Free PMC article.
Review.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Kei Amioka, Tomokazu Kawaoka, +33 authors, Hiroshi Aikata.
Cancers (Basel), 2022 Jan 22; 14(2). PMID: 35053484    Free PMC article.
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
Jing-Houng Wang, Yen-Yang Chen, +7 authors, Yen-Hao Chen.
Cancers (Basel), 2022 Jan 22; 14(2). PMID: 35053508    Free PMC article.
CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma.
Sohji Nishina, Keisuke Hino.
Cancers (Basel), 2022 Jan 22; 14(2). PMID: 35053615    Free PMC article.
Review.
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Davide Ciardiello, Brigida Anna Maiorano, +11 authors, Evaristo Maiello.
Int J Mol Sci, 2022 Jan 22; 23(2). PMID: 35055006    Free PMC article.
Review.
Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.
Anita Bakrania, Gang Zheng, Mamatha Bhat.
Pharmaceutics, 2022 Jan 22; 14(1). PMID: 35056937    Free PMC article.
Review.
Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma.
Fei Yang, Jun Yang, +8 authors, Xiao-Li Zhu.
Front Oncol, 2022 Feb 01; 11. PMID: 35096555    Free PMC article.
Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment.
Sebastian A Wohlfeil, Verena Häfele, +11 authors, Cyrill Géraud.
J Transl Med, 2022 Feb 04; 20(1). PMID: 35109875    Free PMC article.
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Osman Öcal, Kerstin Schütte, +19 authors, Max Seidensticker.
J Cancer Res Clin Oncol, 2021 Apr 16; 148(2). PMID: 33855585    Free PMC article.
Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
Lampros Chrysavgis, Ilias Giannakodimos, Panagiota Diamantopoulou, Evangelos Cholongitas.
World J Gastroenterol, 2022 Feb 04; 28(3). PMID: 35110952    Free PMC article.
Review.
Inflammation in Hepatocellular Carcinoma Patients Undergoing Hepatectomy: An Important Target for Ongoing Study : Editorial Comment on "The Impact of Histological Liver Inflammation on Oncology and the Prognosis of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma".
June S Peng, Niraj J Gusani.
Ann Surg Oncol, 2022 Feb 05; 29(4). PMID: 35119547
Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers.
Ahmet Gulmez, Hakan Harputluoglu.
J Gastrointest Cancer, 2022 Feb 05;. PMID: 35119620
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.
Osman Öcal, Michael Ingrisch, +14 authors, Max Seidensticker.
Br J Cancer, 2021 Oct 24; 126(2). PMID: 34686780    Free PMC article.
Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.
Yi Luo, Fei Teng, Hong Fu, Guo-Shan Ding.
World J Gastrointest Oncol, 2022 Feb 05; 14(1). PMID: 35116109    Free PMC article.
Review.
Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients.
Lixin Ke, Jianming Shen, +10 authors, Yunpeng Hua.
Front Mol Biosci, 2022 Feb 05; 8. PMID: 35118119    Free PMC article.
Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism.
Jelena Krstic, Isabel Reinisch, +22 authors, Andreas Prokesch.
Sci Adv, 2022 Jan 22; 8(3). PMID: 35061544    Free PMC article.
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Jiawei Shi, Junwei Liu, +9 authors, Weijia Fang.
J Immunother Cancer, 2022 Feb 02; 10(1). PMID: 35101942    Free PMC article.
Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.
Bénédicte Delire, Eleonora De Martin, +2 authors, Yves Horsmans.
Front Pharmacol, 2022 Feb 08; 12. PMID: 35126126    Free PMC article.
Review.
The therapeutic effect of IL-21 combined with IFN-γ inducing CD4+CXCR5+CD57+T cells differentiation on hepatocellular carcinoma.
Changlin Zhao, Xianlin Wu, Jia Chen, Guoqiang Qian.
J Adv Res, 2022 Feb 08; 36. PMID: 35127167    Free PMC article.
Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States.
Chenhui Zou, Imane El Dika, +15 authors, Ype P de Jong.
Cancer Med, 2021 Dec 25; 11(3). PMID: 34951132    Free PMC article.
Immunotherapies for hepatocellular carcinoma.
Justin K H Liu, Andrew F Irvine, Rebecca L Jones, Adel Samson.
Cancer Med, 2021 Dec 26; 11(3). PMID: 34953051    Free PMC article.
Review.
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Atsushi Hiraoka, Takashi Kumada, +18 authors, Kazuhiro Nouso.
Oncology, 2021 Nov 30; 100(2). PMID: 34844247    Free PMC article.
[Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].
Sabrina Voesch, M Bitzer, N Malek.
Radiologe, 2022 Feb 12; 62(3). PMID: 35147708
Review.
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
Maxime Bossageon, Aurélie Swalduz, Christos Chouaïd, Olivier Bylicki.
BioDrugs, 2022 Feb 12; 36(2). PMID: 35147894
Review.
Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials.
Sung Hwan Lee, Yun Seong Jeong, +13 authors, Ju-Seog Lee.
Cancer Commun (Lond), 2022 Jan 16; 42(2). PMID: 35032367    Free PMC article.
Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database.
Zhiming Jiao, Ganyi Wang, +5 authors, Da Feng.
Front Pharmacol, 2022 Feb 12; 12. PMID: 35145400    Free PMC article.
Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.
Ruyin Chen, Qiong Li, +5 authors, Jian Ruan.
Cancer Cell Int, 2022 Feb 13; 22(1). PMID: 35148789    Free PMC article.
Review.
TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC.
Boris Guiu, Etienne Garin, +2 authors, Riad Salem.
Cardiovasc Intervent Radiol, 2022 Feb 13;. PMID: 35149884
Review.
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Ahmed Omar Kaseb, Elshad Hasanov, +26 authors, Padmanee Sharma.
Lancet Gastroenterol Hepatol, 2022 Jan 23; 7(3). PMID: 35065057    Free PMC article.
Association of Angiogenesis Gene Expression With Cancer Prognosis and Immunotherapy Efficacy.
Xin-Yu Li, Wei-Ning Ma, +7 authors, Xi-Tao Yang.
Front Cell Dev Biol, 2022 Feb 15; 10. PMID: 35155426    Free PMC article.
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Grazia Graziani, Lucia Lisi, Lucio Tentori, Pierluigi Navarra.
Exp Suppl, 2022 Feb 16; 113. PMID: 35165868
Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers.
Inga Hochnadel, Lisa Hoenicke, +14 authors, Tetyana Yevsa.
Oncogene, 2022 Feb 18; 41(14). PMID: 35173308    Free PMC article.
Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer.
Misty Shuo Zhang, Jane Di Cui, +11 authors, Carmen Chak-Lui Wong.
Nat Commun, 2022 Feb 19; 13(1). PMID: 35177645    Free PMC article.
Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Xiaoqiang Yin, Tongchui Wu, Yadong Lan, Wulin Yang.
Biosci Rep, 2022 Jan 26; 42(2). PMID: 35075482    Free PMC article.
Review.
Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
Dong Dong, Jin-Yu Shi, +4 authors, Nan-Ya Wang.
Medicine (Baltimore), 2022 Feb 05; 101(5). PMID: 35119010    Free PMC article.
Novel Cellular Therapies for Hepatocellular Carcinoma.
Harriet Roddy, Tim Meyer, Claire Roddie.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35158772    Free PMC article.
Review.
Genetic Landscape of Multistep Hepatocarcinogenesis.
Haruhiko Takeda, Atsushi Takai, +3 authors, Hiroshi Seno.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35158835    Free PMC article.
Review.
Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances.
Blanca Cucarull, Anna Tutusaus, +6 authors, Albert Morales.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35158892    Free PMC article.
Review.
Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors.
Hiroshi Maeda, Kouichi Miura, +12 authors, Hironori Yamamoto.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35159018    Free PMC article.
The Role of Macroautophagy and Chaperone-Mediated Autophagy in the Pathogenesis and Management of Hepatocellular Carcinoma.
Anastasia D Karampa, Anna C Goussia, +3 authors, Antonia V Charchanti.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35159028    Free PMC article.
Review.
Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment.
Thorben W Fründt, Christian Casar, +10 authors, Kornelius Schulze.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35159035    Free PMC article.
Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.
Ryu Sasaki, Kazuyoshi Nagata, +13 authors, Kazuhiko Nakao.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35159095    Free PMC article.
BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
Han Chen, Kouki Nio, +11 authors, Shuichi Kaneko.
Int J Mol Sci, 2022 Feb 16; 23(3). PMID: 35163396    Free PMC article.
β-Catenin signaling in hepatocellular carcinoma.
Chuanrui Xu, Zhong Xu, +3 authors, Xin Chen.
J Clin Invest, 2022 Feb 16; 132(4). PMID: 35166233    Free PMC article.
Review.
Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Shuguang Ju, Chen Zhou, +9 authors, Bin Xiong.
Front Oncol, 2022 Feb 18; 11. PMID: 35174073    Free PMC article.
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.
Filippo Pelizzaro, Selion Haxhi, +24 authors, Fabio Farinati.
Front Oncol, 2022 Feb 18; 12. PMID: 35174092    Free PMC article.
Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials.
C W Szeto, R Kurzrock, +5 authors, J J Adashek.
ESMO Open, 2022 Feb 15; 7(1). PMID: 35158206    Free PMC article.
Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study.
Nikunj Patel, Joshua Maher, +11 authors, Gordon Cohen.
Qual Life Res, 2021 Jun 12; 31(2). PMID: 34115280    Free PMC article.
Type I IFNs repolarized a CD169+ macrophage population with anti-tumor potentials in hepatocellular carcinoma.
Jing Liao, Dan-Ni Zeng, +7 authors, Yan Wu.
Mol Ther, 2021 Sep 27; 30(2). PMID: 34563673    Free PMC article.
Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer.
Bruna C Bertol, Elise S Bales, +7 authors, Jena D French.
Thyroid, 2021 Oct 14; 32(2). PMID: 34641722    Free PMC article.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Maria Reig, Alejandro Forner, +13 authors, Jordi Bruix.
J Hepatol, 2021 Nov 22; 76(3). PMID: 34801630    Free PMC article.
Review.
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
Aaron T Gerds, Bart L Scott, +11 authors, William Donnellan.
Blood Adv, 2021 Dec 22; 6(4). PMID: 34932793    Free PMC article.
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Atsushi Hiraoka, Takashi Kumada, +32 authors, Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan).
Cancer Rep (Hoboken), 2021 Jun 12; 5(2). PMID: 34114752    Free PMC article.
A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma.
Xiaoyun Bu, Luyao Ma, +5 authors, Ming Shi.
Cancer Cell Int, 2022 Feb 24; 22(1). PMID: 35193591    Free PMC article.
SLC39A1 Overexpression is Associated with Immune Infiltration in Hepatocellular Carcinoma and Promotes Its Malignant Progression.
Xiaowu Ma, Hongkai Zhuang, +7 authors, Changzhen Shang.
J Hepatocell Carcinoma, 2022 Feb 26; 9. PMID: 35211427    Free PMC article.
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
Yuta Myojin, Takahiro Kodama, +17 authors, Tetsuo Takehara.
Cancers (Basel), 2022 Feb 26; 14(4). PMID: 35205631    Free PMC article.
A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea.
Takayuki Ando, Miho Sakumura, +2 authors, Ichiro Yasuda.
Healthcare (Basel), 2022 Feb 26; 10(2). PMID: 35206833    Free PMC article.
Review.
Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.
Danijel Galun, Dragana Mijac, +3 authors, Dragan Masulovic.
J Pers Med, 2022 Feb 26; 12(2). PMID: 35207638    Free PMC article.
Review.
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
David Repáraz, Belén Aparicio, +2 authors, Pablo Sarobe.
Int J Mol Sci, 2022 Feb 27; 23(4). PMID: 35216137    Free PMC article.
Review.
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer.
Yuchen Guo, Yangyang Zhou, Wenxin Qin.
Cancer Biol Med, 2021 Oct 29;. PMID: 34708999    Free PMC article.
Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders.
Coskun Ozer Demirtas, Gabrielle Ricco, +9 authors, Feyza Gunduz.
Hepatol Commun, 2021 Nov 10; 6(3). PMID: 34751001    Free PMC article.
Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Ye Peng, Xiaohui Zeng, +8 authors, Chongqing Tan.
Front Pharmacol, 2022 Mar 01; 13. PMID: 35222020    Free PMC article.
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
Kennedy Yao Yi Ng, Sze Huey Tan, +7 authors, Joycelyn Jie Xin Lee.
Liver Cancer, 2022 Mar 01; 11(1). PMID: 35222504    Free PMC article.
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
Kazufumi Kobayashi, Sadahisa Ogasawara, +36 authors, Naoya Kato.
Liver Cancer, 2022 Mar 01; 11(1). PMID: 35222507    Free PMC article.
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.
Giuseppe Cabibbo, Maria Reig, +11 authors, Calogero Cammà.
Liver Cancer, 2022 Mar 01; 11(1). PMID: 35222509    Free PMC article.
Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Lijun Xu, Qing Zheng, Wenwen Liu.
BMC Cancer, 2022 Mar 04; 22(1). PMID: 35236323    Free PMC article.
Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.
Antonio Giovanni Solimando, Nicola Susca, +11 authors, Vito Racanelli.
Clin Exp Med, 2021 Jun 20; 22(1). PMID: 34146196    Free PMC article.
Systematic Review.
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Niharika B Mettu, Fang-Shu Ou, +13 authors, Tanios Bekaii-Saab.
JAMA Netw Open, 2022 Feb 19; 5(2). PMID: 35179586    Free PMC article.
A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer.
Chen Yang, Hailin Zhang, +10 authors, Hui Wang.
Elife, 2022 Feb 23; 11. PMID: 35191375    Free PMC article.
Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.
Zhu-Jian Deng, Le Li, +7 authors, Jian-Hong Zhong.
J Clin Transl Hepatol, 2022 Mar 03; 10(1). PMID: 35233384    Free PMC article.
Review.
Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway.
Sun Guangshun, Sun Guoqiang, +8 authors, Tang Weiwei.
J Oncol, 2022 Mar 04; 2022. PMID: 35237322    Free PMC article.
Precision medicine for metastatic colorectal cancer in clinical practice.
Julian E Riedesser, Matthias P Ebert, Johannes Betge.
Ther Adv Med Oncol, 2022 Mar 04; 14. PMID: 35237350    Free PMC article.
Review.
Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.
Yuling Xiao, Jiang Chen, +11 authors, Jinjun Shi.
Nat Commun, 2022 Feb 11; 13(1). PMID: 35140208    Free PMC article.
Inhibition of the VEGF signaling pathway attenuates tumor‑associated macrophage activity in liver cancer.
Shohei Okikawa, Yuji Morine, +8 authors, Mitsuo Shimada.
Oncol Rep, 2022 Feb 17; 47(4). PMID: 35169858    Free PMC article.
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.
Tiago de Castro, Leonie S Jochheim, +13 authors, Anna Saborowski.
Ther Adv Med Oncol, 2022 Mar 08; 14. PMID: 35251317    Free PMC article.
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Danyu Du, Chan Liu, +5 authors, Jing Xiong.
Acta Pharm Sin B, 2022 Mar 09; 12(2). PMID: 35256934    Free PMC article.
Review.
A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma.
Leye Yan, Junqing Lin, +4 authors, Weizhu Yang.
Transl Cancer Res, 2022 Mar 10; 11(1). PMID: 35261888    Free PMC article.
RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues.
Alexander Scheiter, Katja Evert, +17 authors, Kirsten Utpatel.
Mol Oncol, 2021 Nov 09; 16(5). PMID: 34748271    Free PMC article.
Immune-related lncRNA signature delineates an immune-excluded subtype of liver cancer with unfavorable clinical outcomes.
Yawei Chen, Leying Xi, +2 authors, Tianmei Zeng.
J Clin Lab Anal, 2022 Jan 19; 36(3). PMID: 35040184    Free PMC article.
Mutational signatures and processes in hepatobiliary cancers.
Ekaterina Zhuravleva, Colm J O'Rourke, Jesper B Andersen.
Nat Rev Gastroenterol Hepatol, 2022 Mar 12; 19(6). PMID: 35273358
Review.
Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.
Shou-Wu Lee, Sheng-Shun Yang, +3 authors, Teng-Yu Lee.
J Clin Med, 2022 Mar 11; 11(5). PMID: 35268535    Free PMC article.
PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease.
Rosa Lombardi, Roberto Piciotti, +3 authors, Anna Ludovica Fracanzani.
Int J Mol Sci, 2022 Mar 11; 23(5). PMID: 35269846    Free PMC article.
Review.
Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma.
Tsuyoshi Suda, Taro Yamashita, +7 authors, Shuichi Kaneko.
Int J Mol Sci, 2022 Mar 11; 23(5). PMID: 35269944    Free PMC article.
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
Shun Kaneko, Masayuki Kurosaki, +18 authors, Namiki Izumi.
PLoS One, 2022 Mar 11; 17(3). PMID: 35271670    Free PMC article.
Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma.
Qing Yan, Hao-Ming Lin, +6 authors, Rui Zhang.
Front Oncol, 2022 Mar 12; 12. PMID: 35273912    Free PMC article.
Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices.
Andrew J Klink, Landon Z Marshall, +3 authors, Bruce Feinberg.
Oncologist, 2022 Mar 12; 27(3). PMID: 35274709    Free PMC article.
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Ion Agirrezabal, Victoria K Brennan, +4 authors, Valérie Vilgrain.
Adv Ther, 2022 Mar 14; 39(5). PMID: 35279814    Free PMC article.
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.
Min Deng, Shaohua Li, +6 authors, Rongping Guo.
Ann Med, 2022 Mar 12; 54(1). PMID: 35272564    Free PMC article.
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.
Maria Teresa Di Martino, Mariamena Arbitrio, +22 authors, Pierfrancesco Tassone.
Mol Ther Nucleic Acids, 2022 Mar 15; 27. PMID: 35282417    Free PMC article.
Review.
A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.
Joy Awosika, Davendra Sohal.
J Gastrointest Oncol, 2022 Mar 15; 13(1). PMID: 35284102    Free PMC article.
Review.
Hepatocellular carcinoma with complete response to the immunotherapy: the oncologist's dilemma.
Mansour Al-Moundhri, Antonio Cubisino, Fabrizio Panaro.
Hepatobiliary Surg Nutr, 2022 Mar 15; 11(1). PMID: 35284505    Free PMC article.
Regional differences: clinical practice guidelines on the management of hepatocellular carcinoma.
Yuquan Qian, Andreas Teufel.
Hepatobiliary Surg Nutr, 2022 Mar 15; 11(1). PMID: 35284506    Free PMC article.
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
Howard Jack West, Mark McCleland, +11 authors, Mark A Socinski.
J Immunother Cancer, 2022 Feb 23; 10(2). PMID: 35190375    Free PMC article.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.
Giulia Petroni, Aitziber Buqué, Lisa M Coussens, Lorenzo Galluzzi.
Nat Rev Drug Discov, 2022 Mar 17; 21(6). PMID: 35292771
Review.
Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma.
Nekisa Zakeri, Andrew Hall, +10 authors, Mala K Maini.
Nat Commun, 2022 Mar 18; 13(1). PMID: 35296658    Free PMC article.
Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma.
Ze Zhang, Wenwen Zhang, +5 authors, Shichun Lu.
Front Cell Dev Biol, 2022 Mar 18; 10. PMID: 35295858    Free PMC article.
The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma.
Zhixian Wu, Hongwei Cheng, +10 authors, Jin-Zhang Zeng.
J Hepatocell Carcinoma, 2022 Mar 19; 9. PMID: 35300206    Free PMC article.
Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study.
Kongying Lin, Fuqun Wei, +10 authors, Yongyi Zeng.
J Hepatocell Carcinoma, 2022 Mar 19; 9. PMID: 35300207    Free PMC article.
Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Mingyue Cai, Wensou Huang, +9 authors, Kangshun Zhu.
Front Immunol, 2022 Mar 19; 13. PMID: 35300325    Free PMC article.
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced hepatocellular carcinoma with macrovascular invasion.
Giammauro Berardi, Nicola Guglielmo, +9 authors, Giuseppe Maria Ettorre.
Updates Surg, 2022 Mar 20;. PMID: 35305261
System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
Xu Wang, Tao Zhou, +7 authors, Yong Yang.
J Immunother Cancer, 2022 Mar 06; 10(3). PMID: 35246476    Free PMC article.
Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Xuqi Sun, Qi Zhang, +3 authors, Tingbo Liang.
BMC Cancer, 2022 Mar 21; 22(1). PMID: 35305593    Free PMC article.
Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis?
Jung Wan Choe, Hye Yoon Lee, Chai Hong Rim.
World J Gastroenterol, 2022 Mar 24; 28(7). PMID: 35317274    Free PMC article.
Review.
The role of complement in the clinical course of hepatocellular carcinoma.
Xinye Qian, Zhoujing Yang, +2 authors, Jun Yan.
Immun Inflamm Dis, 2021 Nov 24; 10(3). PMID: 34813686    Free PMC article.
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Osama E Rahma, Kevin Tyan, +11 authors, F Stephen Hodi.
J Immunother Cancer, 2022 Mar 11; 10(3). PMID: 35264434    Free PMC article.
Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.
Landon L Chan, Stephen L Chan.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326677    Free PMC article.
Review.
Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.
Eleni Gkika, Anca-Ligia Grosu, +6 authors, Yann Touchefeu.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326718    Free PMC article.
The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Kit Man Wong, Gentry G King, William P Harris.
Curr Oncol Rep, 2022 Mar 30; 24(7). PMID: 35347594
Review.
Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status.
Norifumi Iseda, Shinji Itoh, +16 authors, Masaki Mori.
Hepatol Commun, 2021 Oct 24; 6(4). PMID: 34687175    Free PMC article.
Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis.
Romain Desert, Xiaodong Ge, +12 authors, Natalia Nieto.
Hepatol Commun, 2021 Nov 04; 6(4). PMID: 34730871    Free PMC article.
Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
David J Benjamin, Alexander Xu, Mark P Lythgoe, Vinay Prasad.
JAMA Netw Open, 2022 Mar 16; 5(3). PMID: 35289858    Free PMC article.
Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Shuguang Ju, Chen Zhou, +10 authors, Bin Xiong.
BMC Cancer, 2022 Mar 30; 22(1). PMID: 35346114    Free PMC article.
Bioinformatics Analysis Combined With Experiments Predicts PUDP as a Potential Prognostic Biomarker for Hepatocellular Carcinoma Through Its Interaction With Tumor Microenvironment.
Jiahao Yu, Weirui Zhang, +4 authors, Ying Han.
Front Oncol, 2022 Mar 31; 12. PMID: 35350563    Free PMC article.
Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma.
Weiqiang Fan, Huan Ma, Bin Jin.
Oncol Lett, 2022 Mar 31; 23(5). PMID: 35350587    Free PMC article.
Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity.
Yaoqiang Wu, Han Lin, +4 authors, Xibo Fu.
Front Oncol, 2022 Apr 01; 12. PMID: 35356200    Free PMC article.
Review.
A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Tao Sun, Lei Chen, +5 authors, Chuansheng Zheng.
J Oncol, 2022 Apr 01; 2022. PMID: 35356254    Free PMC article.
ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma.
Shirong Zhang, Longwen Xu, +9 authors, Hui Guo.
Front Genet, 2022 Apr 02; 13. PMID: 35360875    Free PMC article.
Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy.
Jiayong Liu, Peijie Liu, +2 authors, Xiaochen Zhao.
Front Immunol, 2022 Apr 05; 13. PMID: 35371041    Free PMC article.
Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review.
Qin-Qin Liu, Hao-Ming Lin, +3 authors, Rui Zhang.
Front Oncol, 2022 Apr 05; 12. PMID: 35372010    Free PMC article.
CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
Jiang Chen, Shi Jiang, +9 authors, Xiujun Cai.
Sci China Life Sci, 2022 Apr 06;. PMID: 35380342
Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030).
Igor Stukalin, Newaz Shubidito Ahmed, +8 authors, Christopher Ma.
Gastroenterology, 2021 Dec 20; 162(4). PMID: 34922947    Free PMC article.
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Nusayba A Bagegni, Haeseong Park, +11 authors, Andrea Wang-Gillam.
Cancer Chemother Pharmacol, 2022 Mar 06; 89(4). PMID: 35247086    Free PMC article.
Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study.
Weiwei Zhai, Hannah Lai, +40 authors, Pierce Kah-Hoe Chow.
Natl Sci Rev, 2022 Apr 07; 9(3). PMID: 35382356    Free PMC article.
Care of the Hepatology Patient in the COVID-19 Era.
Kathryn E Driggers, Brett W Sadowski, Eva Shagla, Ryan M Kwok.
Curr Hepatol Rep, 2022 Apr 07; 21(2). PMID: 35382426    Free PMC article.
Review.
Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma.
Jin-Xing Zhang, Pei Chen, +3 authors, Chun-Gao Zhou.
J Hepatocell Carcinoma, 2022 Apr 08; 9. PMID: 35388358    Free PMC article.
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.
Yinjie Fan, Hang Xue, Huachuan Zheng.
J Hepatocell Carcinoma, 2022 Apr 08; 9. PMID: 35388357    Free PMC article.
Review.
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Adel Naimi, Rebar N Mohammed, +11 authors, Ehsan Razeghian.
Cell Commun Signal, 2022 Apr 09; 20(1). PMID: 35392976    Free PMC article.
Review.
Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.
Teiji Kuzuya, Naoto Kawabe, +10 authors, Yoshiki Hirooka.
Cancer Diagn Progn, 2022 Apr 12; 1(2). PMID: 35403128    Free PMC article.
Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
Jimmy Charneau, Toshihiro Suzuki, +7 authors, Tetsuya Nakatsura.
Cancer Sci, 2022 Feb 06; 113(4). PMID: 35122353    Free PMC article.
A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes.
Leonardo G Da Fonseca, Paulo C Leonardi, +4 authors, Paulo Herman.
Clin Exp Hepatol, 2022 Apr 14; 8(1). PMID: 35415264    Free PMC article.
Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.
Vera Himmelsbach, Matthias Pinter, +7 authors, Fabian Finkelmeier.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406493    Free PMC article.
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.
Beom Kyung Kim, Jaekyung Cheon, +6 authors, Hong Jae Chon.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406518    Free PMC article.
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Maen Abdelrahim, Abdullah Esmail, +8 authors, Rafik Mark Ghobrial.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406533    Free PMC article.
Review.
Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments.
Darren Cowzer, James J Harding.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406572    Free PMC article.
Review.
Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.
Zuzanna Sas, Ewa Cendrowicz, Isabel Weinhäuser, Tomasz P Rygiel.
Int J Mol Sci, 2022 Apr 13; 23(7). PMID: 35409139    Free PMC article.
Review.
Immune checkpoint inhibitors for cancer and venous thromboembolic events.
Jingyi Gong, Zsofia D Drobni, +13 authors, Tomas G Neilan.
Eur J Cancer, 2021 Oct 19; 158. PMID: 34662835    Free PMC article.
Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials.
Linyan Zeng, Junwei Su, +3 authors, Wei Yu.
Cancer Control, 2022 Apr 15; 29. PMID: 35418272    Free PMC article.
Frontline therapy for advanced hepatocellular carcinoma: an update.
Mehmet Akce, Bassel F El-Rayes, Tanios S Bekaii-Saab.
Therap Adv Gastroenterol, 2022 Apr 19; 15. PMID: 35432597    Free PMC article.
Review.
Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study.
Xiao-Yuan Li, Yang Rao, Bing Sun, Xue-Mei Mao.
Int J Gen Med, 2022 Apr 21; 15. PMID: 35440872    Free PMC article.
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan.
Masashi Fujita, Kazumichi Abe, +14 authors, Hiromasa Ohira.
Sci Rep, 2022 Apr 22; 12(1). PMID: 35444161    Free PMC article.
Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.
Sun Ha Choi, Seung Soo Yoo, Shin Yup Lee, Jae Yong Park.
Arch Pharm Res, 2022 Apr 23; 45(4). PMID: 35449345
Review.
Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial.
Qian Dong, Yanwen Diao, +3 authors, Jingdong Zhang.
BMJ Open, 2022 Apr 06; 12(4). PMID: 35379611    Free PMC article.
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
Daniel M Halperin, Suyu Liu, +23 authors, James C Yao.
JAMA Oncol, 2022 Apr 08; 8(6). PMID: 35389428    Free PMC article.
Adjuvant therapy for periampullary carcinoma and the significance of histopathological typing: A systematic review.
Zhiqing Duan, Yinuo Zhang, +3 authors, Bo Liang.
Transl Oncol, 2022 Apr 10; 20. PMID: 35397420    Free PMC article.
Review.
Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?
Jun Deng, Feng Wen.
Front Oncol, 2022 Apr 16; 12. PMID: 35425716    Free PMC article.
Review.
Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria.
Philippe d'Abadie, Stephan Walrand, +3 authors, François Jamar.
Curr Oncol, 2022 Apr 22; 29(4). PMID: 35448170    Free PMC article.
Review.
COVID-19 and liver cancer: lost patients and larger tumours.
Daniel Geh, Robyn Watson, +34 authors, Helen L Reeves.
BMJ Open Gastroenterol, 2022 Apr 23; 9(1). PMID: 35450934    Free PMC article.
Review.
Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma.
Gohar Shahwar Manzar, Brian Sandeep De, +12 authors, Ethan Bernard Ludmir.
Cancers (Basel), 2022 Apr 24; 14(8). PMID: 35454808    Free PMC article.
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.
Yu Fujiwara, Nobuyuki Horita, +3 authors, Matthew D Galsky.
Cancer Immunol Immunother, 2022 Apr 27;. PMID: 35471602
Review.
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68 Ga-PSMA-11 PET Using Cyclotron-Produced 68 Ga.
Scott M Thompson, Garima Suman, +26 authors, Ajit H Goenka.
Hepatol Commun, 2021 Nov 17; 6(5). PMID: 34783177    Free PMC article.
Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells.
Darko Castven, Carolin Czauderna, +14 authors, Jens U Marquardt.
Hepatol Commun, 2021 Nov 25; 6(5). PMID: 34817932    Free PMC article.
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Satoshi Narahara, Takehisa Watanabe, +14 authors, Yutaka Sasaki.
Hepatol Commun, 2021 Nov 28; 6(5). PMID: 34837478    Free PMC article.
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.
Sadahisa Ogasawara, Keisuke Koroki, +28 authors, Naoya Kato.
BMJ Open, 2022 Apr 10; 12(4). PMID: 35396315    Free PMC article.
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Nikolaos Machairas, Diamantis I Tsilimigras, Timothy M Pawlik.
Cancers (Basel), 2022 Apr 24; 14(8). PMID: 35454923    Free PMC article.
Review.
Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model.
Terufumi Yoshida, Masaki Kaibori, +11 authors, Mitsugu Sekimoto.
Nanomaterials (Basel), 2022 Apr 24; 12(8). PMID: 35458072    Free PMC article.
Immunotherapy for hepatocellular carcinoma: a "CRAFITY" approach to patient stratification.
Salim I Khakoo.
Hepatobiliary Surg Nutr, 2022 Apr 26; 11(2). PMID: 35464263    Free PMC article.
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
Hui-Chuan Sun, Jian Zhou, +77 authors, Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association.
Hepatobiliary Surg Nutr, 2022 Apr 26; 11(2). PMID: 35464283    Free PMC article.
Review.
Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients.
Zili Hu, Xuqi Sun, +6 authors, Minshan Chen.
J Hepatocell Carcinoma, 2022 Apr 27; 9. PMID: 35469289    Free PMC article.
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.
Josep M Llovet, Roser Pinyol, +5 authors, Augusto Villanueva.
Nat Cancer, 2022 Apr 29; 3(4). PMID: 35484418    Free PMC article.
Review.
Dissecting liver tumor heterogeneity to improve health equity.
Lichun Ma, Xin Wei Wang.
Trends Cancer, 2022 Jan 12; 8(4). PMID: 35012904    Free PMC article.
Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers.
C Zhou, J O'Connor, +4 authors, G C Jayson.
ESMO Open, 2022 Mar 14; 7(2). PMID: 35279528    Free PMC article.
Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
Mingye Zhao, Xingming Pan, +4 authors, Wenxi Tang.
Front Public Health, 2022 May 03; 10. PMID: 35493395    Free PMC article.
Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.
Chun-Ming Ho, Kuen-Tyng Lin, +4 authors, Yuh-Shan Jou.
Comput Struct Biotechnol J, 2022 May 03; 20. PMID: 35495118    Free PMC article.
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial.
Shengxiang Ren, Jianxing He, +9 authors, Caicun Zhou.
JTO Clin Res Rep, 2022 May 03; 3(5). PMID: 35498381    Free PMC article.
Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma.
Abdulkadir Elmas, Amaia Lujambio, Kuan-Lin Huang.
Front Oncol, 2022 Apr 19; 12. PMID: 35433463    Free PMC article.
Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.
Sandra Mirie Kang, Lana Khalil, Bassel F El-Rayes, Mehmet Akce.
Front Oncol, 2022 Apr 19; 12. PMID: 35433430    Free PMC article.
Review.
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy.
Shaima Salman, David J Meyers, +11 authors, Gregg L Semenza.
J Clin Invest, 2022 May 03; 132(9). PMID: 35499076    Free PMC article.
Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies.
Yawen Jiang, Dan Cai, Si Shi.
Clin Epidemiol, 2022 May 07; 14. PMID: 35520275    Free PMC article.
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
Masatoshi Kudo.
Int J Clin Oncol, 2022 May 09;. PMID: 35527313
Review.
Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials.
Timothy J Brown, Arjun Gupta, +3 authors, Mark Yarchoan.
Gastrointest Tumors, 2022 May 10; 9(1). PMID: 35528745    Free PMC article.
Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Wei Teng, Chen-Chun Lin, +9 authors, Shi-Ming Lin.
Am J Cancer Res, 2022 May 10; 12(4). PMID: 35530282    Free PMC article.
Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Chung-Wei Su, Ming-Mo Hou, +7 authors, Chen-Chun Lin.
Am J Cancer Res, 2022 May 10; 12(4). PMID: 35530291    Free PMC article.
Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
T Tara Ghaziani, Renumathy Dhanasekaran.
Curr Treat Options Gastroenterol, 2022 May 10; 19(2). PMID: 35530750    Free PMC article.
Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
Li-Hua Li, Wen-Chao Chen, Gang Wu.
Dis Markers, 2022 May 10; 2022. PMID: 35531474    Free PMC article.
Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review).
Guangshun Sun, Hanyuan Liu, +9 authors, Guoqiang Shao.
Int J Oncol, 2022 Apr 30; 60(6). PMID: 35485291    Free PMC article.
Review.
New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Haoer Jin, Sha Qin, +4 authors, Luqing Zhao.
Int J Biol Sci, 2022 May 12; 18(7). PMID: 35541908    Free PMC article.
Review.
Neoantigens as potential vaccines in hepatocellular carcinoma.
David Repáraz, Marta Ruiz, +20 authors, Pablo Sarobe.
J Immunother Cancer, 2022 Feb 24; 10(2). PMID: 35193931    Free PMC article.
Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids.
Zizhen Zhou, Xiaoluan Yan, +5 authors, Yuan Hong.
J Gastrointest Oncol, 2022 May 14; 13(2). PMID: 35557574    Free PMC article.
Comprehensive Analysis of the Correlation Between Pyroptosis-Related LncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma.
Guangzhen Qu, Dong Wang, Weiyu Xu, Wei Guo.
Front Genet, 2022 May 14; 13. PMID: 35559014    Free PMC article.
Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
Nitin N Katariya, Blanca C Lizaola-Mayo, +6 authors, Amit K Mathur.
Cancers (Basel), 2022 May 15; 14(9). PMID: 35565184    Free PMC article.
Review.
Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma.
Kota Hamaguchi, Koji Miyanishi, +12 authors, Junji Kato.
Cancers (Basel), 2022 May 15; 14(9). PMID: 35565198    Free PMC article.
PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma.
Xiuxiang Tan, Jan Bednarsch, +22 authors, Lara Rosaline Heij.
Cancers (Basel), 2022 May 15; 14(9). PMID: 35565318    Free PMC article.
Child-Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib.
Po-Han Huang, Jen Yu, +2 authors, Chau-Ting Yeh.
J Clin Med, 2022 May 15; 11(9). PMID: 35566676    Free PMC article.
MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF.
Nicole Huge, Thea Reinkens, +14 authors, Britta Skawran.
Cancer Cell Int, 2022 May 17; 22(1). PMID: 35578240    Free PMC article.
Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival.
Marcus Alvarez, Jihane N Benhammou, +6 authors, Päivi Pajukanta.
Genome Med, 2022 May 18; 14(1). PMID: 35581624    Free PMC article.
Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma.
Vera Himmelsbach, Mate Knabe, +9 authors, Olivier Ballo.
J Cancer Res Clin Oncol, 2021 Jul 21; 148(6). PMID: 34283288    Free PMC article.
Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis.
Shiguang Chen, Wenchang Yu, +3 authors, Chuanben Chen.
Gastroenterol Rep (Oxf), 2022 May 19; 10. PMID: 35582475    Free PMC article.
Emerging immunotherapy for HCC: A guide for hepatologists.
Friedrich Foerster, Simon Johannes Gairing, Sumera Irie Ilyas, Peter Robert Galle.
Hepatology, 2022 Mar 08; 75(6). PMID: 35253934    Free PMC article.
Review.
Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.
Jin-Xing Zhang, Yu-Xing Chen, +4 authors, Qing-Quan Zu.
Can J Gastroenterol Hepatol, 2022 May 20; 2022. PMID: 35586608    Free PMC article.
Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
Song Zhang, Xin Wang, Hao Gu, Jun-Qi Liu.
Cancer Manag Res, 2022 May 21; 14. PMID: 35592110    Free PMC article.
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Toshifumi Tada, Takashi Kumada, +34 authors, Masatoshi Kudo.
Sci Rep, 2022 May 20; 12(1). PMID: 35589772    Free PMC article.
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.
Julien Calderaro, Tobias Paul Seraphin, Tom Luedde, Tracey G Simon.
J Hepatol, 2022 May 20; 76(6). PMID: 35589255    Free PMC article.
Review.
Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.
Tasuku Nakabori, Yutaro Abe, +11 authors, Kazuyoshi Ohkawa.
JGH Open, 2022 May 24; 6(5). PMID: 35601125    Free PMC article.
Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment.
Shun Kaneko, Kaoru Tsuchiya, +20 authors, Namiki Izumi.
JGH Open, 2022 May 24; 6(5). PMID: 35601130    Free PMC article.
Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis.
Yeong Hak Bang, Choong-Kun Lee, +14 authors, Baek-Yeol Ryoo.
Ther Adv Med Oncol, 2022 May 24; 14. PMID: 35602405    Free PMC article.
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Mototsugu Oya, Shuichi Kaneko, +3 authors, Yutaka Okayama.
Cancer Chemother Pharmacol, 2022 Apr 22; 89(6). PMID: 35445315
Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma.
Shu Shimada, Shinji Tanaka.
Int J Clin Oncol, 2022 May 29;. PMID: 35633441
Review.
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis.
Yusuke Ozeki, Naoya Kanogawa, +28 authors, Naoya Kato.
Int J Clin Oncol, 2022 Jun 16;. PMID: 35704154